var title_f28_27_29104="Breast MRI screening of BRCA carrier";
var content_f28_27_29104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breast MRI screening of BRCA carrier",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast MRI is useful for screening women with genetic mutations that confer a very high risk for breast cancer. The figure depicts a breast MRI that was performed on a BRCA-1 gene carrier, revealing a focal circumscribed mass in left breast not visible on mammography (arrow). MR-guided core biopsy confirmed an invasive ductal carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29104=[""].join("\n");
var outline_f28_27_29104=null;
var title_f28_27_29105="Parts of the eye PI";
var content_f28_27_29105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Parts of the eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross section of an eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29105=[""].join("\n");
var outline_f28_27_29105=null;
var title_f28_27_29106="Cystic Pneumocystis pneumonia";
var content_f28_27_29106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumocystis jiroveci pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan from a patient treated with aerosolized pentamidine. Upper lobe ground glass opacities are interspersed with multiple small cystic spaces that diffusely permeate the lung parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29106=[""].join("\n");
var outline_f28_27_29106=null;
var title_f28_27_29107="Digestive system adult PI";
var content_f28_27_29107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Digestive system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 680px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the organs in the body that process food. Together these organs are called \"the digestive system,\" or \"digestive tract.\" As food travels through this system, the body absorbs nutrients and water.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29107=[""].join("\n");
var outline_f28_27_29107=null;
var title_f28_27_29108="Fluorescein: Drug information";
var content_f28_27_29108=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorescein: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Fluor&reg;;",
"     </li>",
"     <li>",
"      BioGlo&trade;;",
"     </li>",
"     <li>",
"      Fluorescite&reg;;",
"     </li>",
"     <li>",
"      Fluorets&reg;;",
"     </li>",
"     <li>",
"      Ful-Glo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fluorescite&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F172419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F172392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diagnostic staining:",
"     </b>",
"     Ophthalmic: Strips: Moisten strip with sterile water, saline or ophthalmic fluid. Touch conjunctiva or fornix with tip of strip until adequately stained.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic angiography:",
"     </b>",
"     Solution for injection:",
"     <b>",
"      Note:",
"     </b>",
"     Prior to use, an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30-60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 500 mg as a single dose into antecubital vein; a dose of 200 mg may be appropriate in cases when a highly sensitive imaging system (eg, scanning laser ophthalmoscope) is used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral (unlabeled route): 1 g of injection solution has been administered orally; clarity of photographs, particularly during early arterial phase, is reportedly poorer than photographs obtained following I.V. administration (Hara, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F172404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diagnostic staining:",
"     </b>",
"     Ophthalmic: Strips: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic angiography:",
"     </b>",
"     Solution for injection:",
"     <b>",
"      Note:",
"     </b>",
"     Prior to use, an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30-60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 3.5 mg/lb (7.7 mg/kg) as a single dose into antecubital vein; maximum 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F172393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5095158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15405178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium: 10% (5 mL); 25% (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AK-Fluor&reg;: 10% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluorescite&reg;: 10% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Strip, ophthalmic, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BioGlo&trade;: 1 mg (100s, 300s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluorets&reg;: 1 mg (100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ful-Glo&reg;: 0.6 mg (300s); 1 mg (100s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5095179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: A 23-gauge butterfly needle attached to a small syringe is suggested for administration. Prior to turning off room light, steps should be taken to ensure the needle has not extravasated. Immediate treatment for anaphylaxis (including epinephrine 1:1000) should be available and premedication or a test dose may be advised in some patients. Inject the dose into the antecubital vein over 5-10 seconds. Luminescence appears in the eye 7-30 seconds following injection. Maintain venous access following procedure in the event treatment is needed for anaphylaxis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral (unlabeled route): The solution for injection has been administered orally in certain patients. Four grams of sugar or 1 teaspoonful of artificial sweetener may be added to decrease the bitterness of the solution. Luminescence appears in 10-15 minutes following oral administration (Hara, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic: Strips: Fluorescein impregnated tip should be moistened prior to application. Strip should be applied to conjunctiva or fornix. For best results, patient should blink several times after application.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Diagnostic aid in ophthalmic angiography and angioscopy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic: To stain the anterior segment of the eye for procedures (such as fitting contact lenses), disclosing corneal injury, and in applanation tonometry",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F172417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Reactions associated with use of the injection. Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest (rare), basilar artery ischemia (rare), hypotension,  shock, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, seizure (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hives, itching,  pruritus, urticaria, skin discoloration (yellow)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: GI distress, nausea (common), taste disturbance, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary:  Urine discoloration (bright yellow)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Dermatitis, extravasation, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Respiratory: Bronchospasm",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Hemolytic anemia, localized nerve palsy, pulmonary edema (acute), respiratory arrest, sickle crisis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F172387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluorescein or any other component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F172377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur following injection; immediate treatment (including epinephrine 1:1000) should be available. Premedicating some patients (eg, antihistamines, corticosteroids) may be advisable. An intradermal skin test may be performed prior to use when allergy is suspected; however, a negative skin test does not rule out the potential for a reaction to occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin/urine discoloration: Following use of the injection, skin may temporarily turn a yellow color within a few minutes of administration and usually fades in 6-12 hours. Urine may appear bright yellow for 24-36 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergies/asthma: Use with caution in patients with history of hypersensitivity, allergies, or asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Ophthalmic products should not be used in patients with soft contact lenses, will cause them to discolor. Flush eyes with saline following use and wait at least 1hour prior to replacing contact lenses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: For administration via antecubital vein only; not for intrathecal or arterial injection. Avoid extravasation; severe local tissue damage may result, including skin sloughing, phlebitis, toxic neuritis. Following extravasation, severe pain may last up to several hours. Discontinue immediately if extravasation occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5095147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Some manufacturers suggest avoiding angiography during the 1st trimester of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5095149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5095150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Milk discoloration may occur following fluorescein injection.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluorescite Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (5 mL): $44.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Strip",
"     </b>",
"     (Bio Glo Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $14.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Strip",
"     </b>",
"     (Fluor-I-Strips A.T. Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (300): $77.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Strip",
"     </b>",
"     (Ful-Glo Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg (300): $36.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $14.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5095183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection: Monitor for hypersensitivity reactions during procedure and after.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F172388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aka-Fluor (PE);",
"     </li>",
"     <li>",
"      Cendo Fluorescein (ID);",
"     </li>",
"     <li>",
"      Colircusi Fluoresceina (ES);",
"     </li>",
"     <li>",
"      Colirio Ocul Fluorescein (ES);",
"     </li>",
"     <li>",
"      Fluocyne (FR);",
"     </li>",
"     <li>",
"      Fluoftal (AT);",
"     </li>",
"     <li>",
"      Fluor-I-Strip (NL);",
"     </li>",
"     <li>",
"      Fluoralfa (IT);",
"     </li>",
"     <li>",
"      Fluore Stain Strips (IN);",
"     </li>",
"     <li>",
"      Fluorecite (NO);",
"     </li>",
"     <li>",
"      Fluorescein (DE, HR);",
"     </li>",
"     <li>",
"      Fluoresceina (BR);",
"     </li>",
"     <li>",
"      Fluoresceina Oculos (ES);",
"     </li>",
"     <li>",
"      Fluoresceine (IL, LU);",
"     </li>",
"     <li>",
"      Fluoresceine Ophtadose (BE);",
"     </li>",
"     <li>",
"      Fluoresceine SDU Faure (CH);",
"     </li>",
"     <li>",
"      Fluoresceinnatrium (SE);",
"     </li>",
"     <li>",
"      Fluorescite (AE, AR, AU, BF, BH, BJ, CI, CL, CY, CZ, EC, EE, EG, ET, GH, GM, GN, HK, HN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, PL, QA, SA, SC, SD, SG, SL, SN, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Fluorets (GB, HK, IE, MY);",
"     </li>",
"     <li>",
"      Minims Fluorescein Sodium (FI, GB);",
"     </li>",
"     <li>",
"      Minims Fluoresceine (BE);",
"     </li>",
"     <li>",
"      Ophth-fluorstrip (PK);",
"     </li>",
"     <li>",
"      Optifluor Diba (MX);",
"     </li>",
"     <li>",
"      Retinofluor (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F172376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluorescein sodium, a fluoresce dye, responds to wavelengths between 465-490 nm of electromagnetic radiation and light, and fluoresces at wavelengths of 520-530 nm.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15405175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Rapidly metabolized to fluorescein monoglucuronide (~80% is metabolized 1 hour following I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hara T, Inami M, and Hara T. &ldquo;Efficacy and Safety of Fluorescein Angiography With Orally Administered Sodium Fluorescein,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 1998, 126(4):560-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29108/abstract-text/9780101/pubmed\" id=\"9780101\" target=\"_blank\">",
"        9780101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan AS, Barry C, McAllister IL, et al, &ldquo;Fluorescein Angiography and Adverse Drug Reactions Revisited: The Lions Eye Experience,&rdquo;",
"      <i>",
"       Clin Experiment Ophthalmol",
"      </i>",
"      , 2006, 34(1):33-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29108/abstract-text/16451256/pubmed\" id=\"16451256\" target=\"_blank\">",
"        16451256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8461 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-5203FA14AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29108=[""].join("\n");
var outline_f28_27_29108=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172390\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172391\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172419\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172392\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172404\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172393\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095158\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15405178\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172384\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172373\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095179\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172385\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172417\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172387\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172377\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299351\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220438\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172380\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095147\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095149\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095150\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323157\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095183\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172388\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172376\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15405175\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_27_29109="Vasodilator therapy in chronic mitral regurgitation";
var content_f28_27_29109=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vasodilator therapy in chronic mitral regurgitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/27/29109/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29109/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/27/29109/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29109/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/27/29109/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29109/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/27/29109/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe mitral regurgitation (MR), especially those with heart failure, may experience a dramatic hemodynamic improvement during intravenous vasodilator therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/1\">",
"     1",
"    </a>",
"    ]. Based in part upon these observations, it would seem reasonable to consider the use of oral vasodilators in selected patients with chronic MR.",
"   </p>",
"   <p>",
"    Candidates for such therapy could include certain patients who are not candidates for surgery, particularly those with end-stage decompensated MR, and those with compensated MR in whom surgery is not yet indicated. In the latter group, the goal of vasodilator therapy might be to reduce the rate of progression of the hemodynamic burden and, therefore, to delay the onset of symptoms and the need for corrective surgery.",
"   </p>",
"   <p>",
"    An overview of the management of chronic MR is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link\">",
"     \"Overview of the management of chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF REGURGITANT VOLUME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of mitral regurgitant volume is determined hydraulically by two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The duration (D) and magnitude of the systolic pressure gradient across the valve; the latter is determined by the difference between the left ventricular and left atrial systolic pressures (LVP and LAP). It can be especially important to consider the duration of the systolic pressure gradient in the evaluation of patients with mitral valve prolapse [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The mitral regurgitant orifice area (MROA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following formula can be used to estimate the mitral regurgitant volume [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;MRV &nbsp;= &nbsp;MROA &nbsp;x &nbsp;constant &nbsp;x &nbsp;D &nbsp;x &nbsp;sq rt (LVP &nbsp;- &nbsp;LAP)",
"   </p>",
"   <p>",
"    Since the magnitude and duration of the pressure gradient and the orifice area can vary, it is possible to explain the effects of hemodynamic interventions and therapies on the regurgitant volume. Depending upon the clinical setting, vasodilators can decrease or increase regurgitant flow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs with vasodilator activity, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      , angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers, can reduce the regurgitant flow in symptomatic patients and those with heart failure, especially when due to papillary muscle dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/1,4,5\">",
"       1,4,5",
"      </a>",
"      ]. This beneficial effect is mediated by a decrease in ventricular and annular size, which reduces the effective regurgitant orifice area; there may be little or no change in the pressure gradient across the mitral valve [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Venodilators may have the opposite effect in patients with mitral valve prolapse and some with hypertrophic cardiomyopathy, augmenting mitral regurgitant flow via an influence on ventricular size and mitral leaflet coaptation, and duration of the MR [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Venodilation can also increase the regurgitant volume in patients with fixed orifice MR (eg, rheumatic or calcific disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/1\">",
"       1",
"      </a>",
"      ]. In this setting, venodilation can reduce pulmonary venous pressure, leading to a fall in left atrial pressure that may be greater than the reduction in left ventricular systolic pressure, thereby increasing the pressure gradient favoring regurgitation. By contrast, a pure reduction in systolic pressure would reduce mitral regurgitation, especially in the hypertensive patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arterial dilation reduces left ventricular systolic pressure and afterload. Left ventricular afterload is usually normal in compensated and increased in decompensated MR [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], but afterload is not a primary determinant of regurgitant flow [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute vasodilator therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of acute vasodilator therapy in patients with chronic MR has primarily been evaluated in symptomatic patients with heart failure with variable results that depend upon the drug used and the mechanism of MR.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      decreases left ventricular end-diastolic pressure and volume and regurgitant flow, while increasing forward stroke volume and cardiac index [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/1,9-12\">",
"       1,9-12",
"      </a>",
"      ]. The left ventricular ejection fraction is usually unchanged, as there is a roughly equivalent reduction in regurgitant flow and increase in forward flow [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       Hydralazine",
"      </a>",
"      , which is primarily an arterial dilator, also increases forward flow but does not decrease ventricular end-diastolic pressure or volume [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. The benefits are most pronounced when the MR is secondary to left ventricular dysfunction.",
"     </li>",
"     <li>",
"      The effects of acute administration of ACE inhibitors or nitrates appear to be less consistent. Although the regurgitant volume may decrease, there is usually a reduction or no change in the cardiac index [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/15-20\">",
"       15-20",
"      </a>",
"      ]. Furthermore, for the reasons noted above, the acute administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      in patients with rheumatic mitral regurgitation can produce an increase in regurgitant flow for the reasons noted above [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic vasodilator therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data concerning the efficacy of long-term oral vasodilator therapy in patients with chronic MR. The results from small, mostly uncontrolled studies of varying causes of MR are less impressive than would have been predicted from the effects of short-term intravenous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/4,14,21-24\">",
"     4,14,21-24",
"    </a>",
"    ]. Although the regurgitant volume may fall, the average change is generally modest and there is substantial interpatient variability in response.",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings in symptomatic patients with secondary (functional) MR due to heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an initial report, 15 symptomatic patients (New York Heart Association [NYHA] class III to IV), (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) were treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and followed for 13 months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/14\">",
"       14",
"      </a>",
"      ]. The etiology of MR was mixed. Eight patients achieved a sustained symptomatic improvement, while the remaining patients had either intolerable side effects or failed to improve.",
"     </li>",
"     <li>",
"      A combination of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      (average 55",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      up to 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      (average 286",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      up to 480",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was administered for 12 months to 19 patients with severe secondary MR and NYHA class III to IV heart failure (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/21\">",
"       21",
"      </a>",
"      ]. For the group as a whole, there was a significant reduction in NYHA class (3 versus 1.6) and hospitalizations for heart failure, and an increase in peak oxygen consumption. MR reduced to grade 0 to 1 in eight patients and remained at grade 3 to 4 in 11; MR responders had a significantly smaller initial left ventricular end-diastolic diameter compared to nonresponders (6.4 versus 7 cm) and a diameter &le;6.8 cm had a sensitivity and specificity of 83 percent for predicting MR improvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two small randomized trials have evaluated the efficacy of ACE inhibitors in asymptomatic patients with chronic primary MR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized controlled trial, the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      (25 mg TID) was compared to placebo in a study of 32 largely asymptomatic patients (NYHA class I to II), (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) with chronic rheumatic MR [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/23\">",
"       23",
"      </a>",
"      ]. After six months, there was no difference in systolic arterial pressure, left ventricular volume, or ejection fraction between the two groups. It was concluded that captopril had no effect on left ventricular size or performance in patients with severe MR but mild or no symptoms.",
"     </li>",
"     <li>",
"      In a second controlled trial, 23 asymptomatic patients with moderate MR and normal left ventricular function were assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      or placebo for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/24\">",
"       24",
"      </a>",
"      ]. The MR fraction fell by 6.4 percent with lisinopril compared to a 3.7 percent increase with placebo. However, there was no change in left atrial or left ventricular dimensions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data about the efficacy of angiotensin II receptor blockers in chronic MR in humans are limited and suggest only modest benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/4\">",
"     4",
"    </a>",
"    ]. In an animal study of new onset MR, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"     irbesartan",
"    </a>",
"    for three months reduced systemic vascular resistance compared to no therapy, but had no effect on cardiac output or progressive left ventricular enlargement and remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, benefit has primarily been found in patients with moderate to severe symptoms with secondary MR due to left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/14,21,22\">",
"     14,21,22",
"    </a>",
"    ], while asymptomatic patients with primary valve disease appear to exhibit little or no improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In chronic MR, intravenous vasodilator therapy can provide significant hemodynamic improvement, but long-term oral vasodilator therapy is not uniformly beneficial. Nevertheless, some recommendations can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short-term vasodilator therapy with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      is an effective and reliable treatment for patients with severe MR, especially those with secondary MR due to dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/1,9-12\">",
"       1,9-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are no published studies that support the hypothesis that vasodilator therapy is beneficial in",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      patients with chronic primary MR [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/1,3,23,24,26\">",
"       1,3,23,24,26",
"      </a>",
"      ]. Furthermore, it is possible that such therapy might limit symptoms despite worsening ventricular function, possibly masking the usual indications for surgery. Consistent with this hypothesis is the experimental observation noted above that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"       irbesartan",
"      </a>",
"      reduced systemic vascular resistance but did not affect progressive left ventricular enlargement and remodeling [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chronic vasodilator therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, ACE inhibitors or angiotensin II receptor blockers can be given when there is another indication for their use such as hypertension, left ventricular dysfunction, or diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic vasodilator therapy is indicated in",
"      <strong>",
"       symptomatic",
"      </strong>",
"      patients who are not candidates for surgery. The evidence of benefit is best in patients with secondary (functional) MR due to left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29109/abstract/14,21,22\">",
"       14,21,22",
"      </a>",
"      ]. Treatment of such patients should consist of optimal medical therapy of heart failure and, in appropriate patients, cardiac resynchronization therapy. With respect to ACE inhibitors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angiotensin II receptor blockers, the dose titration and monitoring schedules are the same as for heart failure due to left ventricular systolic dysfunction in the absence of moderate to severe MR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"       \"Functional mitral regurgitation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"       \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In hypertensive patients with mitral valve prolapse, a pure reduction in preload can promote regurgitation. The primary goal should be to reduce arterial pressure, particularly in hypertensive patients. Thus, a beta blocker, perhaps in combination with a diuretic, can be used. Beta blockers lower the systolic pressure without reducing left ventricular chamber size.",
"     </li>",
"     <li>",
"      In symptomatic patients with rheumatic MR, there is little potential to induce a change in the regurgitant orifice area via preload reduction and the therapeutic goal should be a reduction in systolic pressure. Thus, a beta blocker, diuretic,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , or calcium channel blocker should be used.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/1\">",
"      Levine HJ, Gaasch WH. Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol 1996; 28:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/2\">",
"      Topilsky Y, Michelena H, Bichara V, et al. Mitral valve prolapse with mid-late systolic mitral regurgitation: pitfalls of evaluation and clinical outcome compared with holosystolic regurgitation. Circulation 2012; 125:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/3\">",
"      Gaasch WH, Aurigemma GP. Inhibition of the renin-angiotensin system and the left ventricular adaptation to mitral regurgitation. J Am Coll Cardiol 2002; 39:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/4\">",
"      Dujardin KS, Enriquez-Sarano M, Bailey KR, et al. Effect of losartan on degree of mitral regurgitation quantified by echocardiography. Am J Cardiol 2001; 87:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/5\">",
"      Rosario LB, Stevenson LW, Solomon SD, et al. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J Am Coll Cardiol 1998; 32:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/6\">",
"      Wisenbaugh T, Spann JF, Carabello BA. Differences in myocardial performance and load between patients with similar amounts of chronic aortic versus chronic mitral regurgitation. J Am Coll Cardiol 1984; 3:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/7\">",
"      Corin WJ, Monrad ES, Murakami T, et al. The relationship of afterload to ejection performance in chronic mitral regurgitation. Circulation 1987; 76:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/8\">",
"      Zile MR, Gaasch WH, Levine HJ. Left ventricular stress-dimension-shortening relations before and after correction of chronic aortic and mitral regurgitation. Am J Cardiol 1985; 56:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/9\">",
"      Chatterjee K, Parmley WW, Swan HJ, et al. Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus. Circulation 1973; 48:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/10\">",
"      Goodman DJ, Rossen RM, Holloway EL, et al. Effect of nitroprusside on left ventricular dynamics in mitral regurgitation. Circulation 1974; 50:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/11\">",
"      Harshaw CW, Grossman W, Munro AB, McLaurin LP. Reduced systemic vascular resistance as therapy for severe mitral regurgitation of valvular origin. Ann Intern Med 1975; 83:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/12\">",
"      Sasayama S, Ohyagi A, Lee JD, et al. Effect of the vasodilator therapy in regurgitant valvular disease. Jpn Circ J 1982; 46:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/13\">",
"      Greenberg BH, Massie BM, Brundage BH, et al. Beneficial effects of hydralazine in severe mitral regurgitation. Circulation 1978; 58:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/14\">",
"      Greenberg BH, DeMots H, Murphy E, Rahimtoola SH. Arterial dilators in mitral regurgitation: effects on rest and exercise hemodynamics and long-term clinical follow-up. Circulation 1982; 65:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/15\">",
"      Wisenbaugh T, Essop R, Rothlisberger C, Sareli P. Effects of a single oral dose of captopril on left ventricular performance in severe mitral regurgitation. Am J Cardiol 1992; 69:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/16\">",
"      R&ouml;thlisberger C, Sareli P, Wisenbaugh T. Comparison of single dose nifedipine and captopril for chronic severe mitral regurgitation. Am J Cardiol 1994; 73:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/17\">",
"      Sch&ouml;n HR, Schr&ouml;ter G, Bl&ouml;mer H, Sch&ouml;mig A. Beneficial effects of a single dose of quinapril on left ventricular performance in chronic mitral regurgitation. Am J Cardiol 1994; 73:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/18\">",
"      Sniderman AD, Marpole DG, Palmer WH, Fallen EL. Response of the left ventricle to nitroglycerin in patients with and without mitral regurgitation. Br Heart J 1974; 36:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/19\">",
"      Elkayam U, Roth A, Kumar A, et al. Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation. Am J Cardiol 1987; 60:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/20\">",
"      Jeang MK, Petrovich LJ, Adyanthaya AV, Alexander J. Effects of isosorbide dinitrate on rheumatic and non-rheumatic mitral regurgitation. Tex Heart Inst J 1986; 13:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/21\">",
"      Levine AB, Muller C, Levine TB. Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling. Am J Cardiol 1998; 82:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/22\">",
"      Sch&ouml;n HR, Schr&ouml;ter G, Barthel P, Sch&ouml;mig A. Quinapril therapy in patients with chronic mitral regurgitation. J Heart Valve Dis 1994; 3:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/23\">",
"      Wisenbaugh T, Sinovich V, Dullabh A, Sareli P. Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis 1994; 3:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/24\">",
"      Marcotte F, Honos GN, Walling AD, et al. Effect of angiotensin-converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function. Can J Cardiol 1997; 13:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/25\">",
"      Perry GJ, Wei CC, Hankes GH, et al. Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol 2002; 39:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29109/abstract/26\">",
"      Iung B, Gohlke-B&auml;rwolf C, Tornos P, et al. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J 2002; 23:1253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8152 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29109=[""].join("\n");
var outline_f28_27_29109=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINANTS OF REGURGITANT VOLUME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute vasodilator therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic vasodilator therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8152\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8152|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_27_29110="Leuprolide and norethindrone: Drug information";
var content_f28_27_29110=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Leuprolide and norethindrone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16054539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin Releasing Hormone Agonist;",
"     </li>",
"     <li>",
"      Progestin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16335688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Endometriosis:",
"     </b>",
"     Females:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment consists of an oral norethindrone tablet used in conjunction with an I.M. leuprolide injection. The initial therapy should be limited to 6 months duration; a single retreatment of not more than 6 additional months may be administered if symptoms recur. Maximum total duration of therapy is 12 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Injection: I.M.: Leuprolide acetate 11.25 mg as a single dose administered by healthcare provider once every 3 months for up to 2 doses (maximum initial therapy: 6 months; maximum cumulative therapy: 12 months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet: Oral: Norethindrone acetate 5 mg once daily for up to 6 months (maximum initial therapy: 6 months; maximum cumulative therapy: 12 months)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F16335687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for use prior to menarche",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16335689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for use in postmenopausal women",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16335690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16335691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied). Use is contraindicated with hepatic tumors or disease.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16335558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16054502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lupaneta Pack: FDA approved December 2012: anticipated availability is early third quarter of 2013. Refer to prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16335692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Leuprolide: Administer I.M. in the gluteal area, anterior thigh, or deltoid. Do not use if a blood vessel is accidently penetrated (will be able to see aspirated blood below the transparent luer lock).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Norethindrone: Administer orally.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16054360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of initial and recurrent painful symptoms of endometriosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16339831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (46% to 51%), depression (27% to 34%), pain (21% to 29%), insomnia (13% to 15%), dizziness (7% to 11%), nervousness (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic:	Dermatological reaction (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hot flash (57% to 87%), decreased HDL cholesterol (41% to 44%), androgen-like effect (5% to 18%), breast changes (8% to 13%), increased LDL cholesterol (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea and vomiting (13% to 29%), constipation/diarrhea (10% to 15%), weight gain (4% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Vaginitis (8% to 15%), irregular menses (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Musculoskeletal: Weakness (11% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (7% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Memory impairment (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Increased serum triglycerides (9% to 10%), decreased libido (4% to 7%), increased gamma-glutamyl transferase (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (4% to 7%), change in appetite (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Increased serum ALT (2%; &ge;2 x ULN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reaction (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Musculoskeletal: Leg cramps (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reaction, asthma, nephrolithiasis, urinary tract infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16335563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to leuprolide, gonadotropin-releasing hormone (GnRH), GnRH-agonist analogs, norethindrone acetate, or any component of the formulation; undiagnosed abnormal uterine bleeding; breast cancer or other hormone-dependent neoplasms (current or a history of); hepatic tumors or disease; thrombotic or thromboembolic disorder (current or history of); pregnancy (or planned pregnancy during therapy); breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16335564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Allergic reactions: Anaphylactoid reactions and asthma exacerbations have been reported with therapy in patients with histories of asthma, sinusitis, or environmental or drug allergies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Decreased bone density: Leuprolide acetate depot suspension may cause an irreversible loss in bone mineral density (BMD). Norethindrone acetate reduces this loss; however, use of this combination should be limited in duration. The initial therapy should be limited to 6 months duration; a single retreatment of not more than 6 additional months may be administered if symptoms recur. BMD should be measured prior to retreatment. Maximum total duration of therapy is 12 months. Use caution in patients with additional risk factors for bone loss (eg, chronic alcohol or tobacco use, strong family history of osteoporosis, chronic use of medications that may decrease BMD such as corticosteroid therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Endometriosis: Due to the physiologic effects of the drug, exacerbation of endometriosis symptoms may occur after the first dose of leuprolide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Visual disturbances: Discontinue norethindrone acetate pending examination if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue this combination permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for arterial disease or venous thromboembolism (VTE) (eg, hypertension, hypercholesterolemia, obesity, diabetes, family history of VTE, or women who smoke). Manage risk factors prior to therapy; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Depression: Use with caution in patients with depression. Depression may occur or worsen during therapy; discontinue if serious depression recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes, or cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy: Pregnancy must be excluded prior to the start of treatment. Although leuprolide usually inhibits ovulation and stops menstruation, contraception is not ensured and a nonhormonal contraceptive should be used. Advise patients to notify their provider if they suspect or become pregnant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Injection: Due to differing release characteristics, this formulation of leuprolide acetate depot suspension is not equivalent to fractional doses of the monthly formulation and cannot be substituted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16369078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16369076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F16335611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase risk of osteoporosis).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16335559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16335560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed with leuprolide in animal reproduction studies. Pregnancy must be excluded prior to the start of treatment. Although leuprolide usually inhibits ovulation and stops menstruation, contraception is not ensured and a nonhormonal contraceptive should be used. Use in pregnant women or women who may be planning a pregnancy during therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fertility suppression observed with other leuprolide formulations is reversible following discontinuation of therapy. This formulation is indicated to treat pain associated with endometriosis; in infertile women with endometriosis, it does not necessarily improve the ability to conceive (ACOG, 2010; ASRM, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16335561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leuprolide: Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16335562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if leuprolide is excreted into breast milk. Small amounts of progestins can be detected in breast milk. Use in nursing women is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F16335616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In clinical trials, women were given supplemental elemental calcium 1000 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16335751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy test (prior to therapy); bone mineral density (prior to retreatment); endometrial-related pain; serum lipids",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16335615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leuprolide administration inhibits the production of estrogen through negative feedback of pituitary gonadotropins. This in turn decreases endometrial implants and symptoms of endometriosis such as pain. Norethindrone is used to decrease adverse events observed with the hypoestrogenic state caused by leuprolide and possibly mitigate bone mineral density loss (Surrey, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16335618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual monographs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists (ACOG), \"Practice Bulletin no. 114: Management of Endometriosis,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2010, 116(1):223-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29110/abstract-text/20567196/pubmed\" id=\"20567196\" target=\"_blank\">",
"        20567196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hornstein MD, Surrey ES, Weisberg GW, et al, \"Leuprolide Acetate Depot and Hormonal Add-Back in Endometriosis: A 12-Month Study. Lupron Add-Back Study Group,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1998, 91(1):16-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29110/abstract-text/9464714/pubmed\" id=\"9464714\" target=\"_blank\">",
"        9464714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Practice Committee of the American Society for Reproductive Medicine (ASRM), \"Endometriosis and Infertility: A Committee Opinion,\"",
"      <i>",
"       Fertil Steril",
"      </i>",
"      ,  2012, 98(3):591-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Surrey ES, \"Gonadotropin-Releasing Hormone Agonist and Add-Back Therapy: What Do the Data Show?\"",
"      <i>",
"       Curr Opin Obstet Gynecol",
"      </i>",
"      , 2010, 22(4):283-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29110/abstract-text/20498596/pubmed\" id=\"20498596\" target=\"_blank\">",
"        20498596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87803 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29110=[""].join("\n");
var outline_f28_27_29110=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16054539\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335688\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335687\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335689\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335690\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335691\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335558\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16054502\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335692\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16054360\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16339831\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335563\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335564\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369078\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369076\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335611\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335559\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335560\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335561\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335562\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335616\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335751\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335615\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335618\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_27_29111="CAA perivascular inflammation";
var content_f28_27_29111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    CAA-related perivascular inflammation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 631px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. T2 weighted axial MR image shows periventricular white matter hyperintensity in a patient who presented with memory difficulties. B. Gradient echo MR image from the same patient shows multiple low intensity foci (red arrows) consistent with microhemorrhages, which are not seen on the T2 weighted image (A). The microhemorrhages are located peripherally, as opposed to hypertensive related hemorrhages that may occur centrally. C. FLAIR MR image demonstrates patchy and confluent periventricular white matter hyperintensity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29111=[""].join("\n");
var outline_f28_27_29111=null;
var title_f28_27_29112="Overview of pulmonary function testing in children";
var content_f28_27_29112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of pulmonary function testing in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/27/29112/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29112/contributors\">",
"     Dennis M Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29112/contributors\">",
"     Andrew A Colin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/27/29112/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29112/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/27/29112/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29112/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/27/29112/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing (PFT) in children plays an important role in the evaluation of the child with known or suspected respiratory disease. It allows for assessment of normal lung and airway growth, the natural history of diseases (eg, bronchopulmonary dysplasia, cystic fibrosis), the site and type of obstruction (central versus peripheral, intrathoracic versus extrathoracic, fixed versus variable), the impact of therapies (eg, bronchodilators, glucocorticoids, diuretics, mucolytics), and the degree of impairment. PFT can also be used to assess the impact of environmental factors (eg, tobacco smoke, toxic gases) and the degree of airway reactivity. In addition, PFT can aid in preoperative assessment of the child with chronic lung disease or neuromuscular weakness. Furthermore, measures of lung function (eg, FEV1) have prognostic value with regards to mortality in some diseases like cystic fibrosis.",
"   </p>",
"   <p>",
"    PFT is recommended by the National Asthma Education and Prevention Program (NAEPP) and the Global Initiative for Asthma (GINA) in the assessment and long-term monitoring of patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/1\">",
"     1",
"    </a>",
"    ]. There is a growing need for pulmonary function testing as the incidence of childhood asthma continues to rise. The development of compact and affordable instruments also enables pediatric lung function testing in the primary care setting.",
"   </p>",
"   <p>",
"    A basic approach to PFT for the primary care provider is presented here. The goal is to encourage pediatricians to obtain PFT to diagnose and monitor the pathophysiologic aspects of their patients' respiratory conditions, thereby improving management.",
"   </p>",
"   <p>",
"    Conventional tests that are frequently performed in the evaluation of pediatric respiratory conditions include measurements that identify:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airway obstruction",
"     </li>",
"     <li>",
"      Restrictive lung, chest wall, and respiratory muscle defects",
"     </li>",
"     <li>",
"      Diffusion defects (those that impair diffusion of gas through the alveolar-capillary membrane)",
"     </li>",
"     <li>",
"      Respiratory muscle weakness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurements of flow and volume are most useful in the office setting. Spirometry, which provides both these measures, requires neither sophisticated technology nor expensive equipment, is easily interpreted, and is reliable when performed correctly. A brief discussion of the technique, clinical applications for, and limitations of more sophisticated measurements of lung volume, diffusion capacity, and respiratory muscle function also is provided so that referrals for such testing can be made appropriately.",
"   </p>",
"   <p>",
"    Readers interested in a more comprehensive review of pulmonary function testing in children are referred elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interpretation of arterial blood gas analyses and exhaled nitric oxide, exercise testing, assessment of bronchial hyperresponsiveness, sleep studies, measurements of control of breathing, and PFT in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=see_link\">",
"     \"Exhaled nitric oxide analysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43513?source=see_link\">",
"     \"Overview of aerobic exercise testing in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\", section on 'Polysomnography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SPIROMETRY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry is the measurement of breathing over time. It includes measures of flow and volume generated by a forced and complete exhalation to residual volume after a full inspiration. The volume-time curve graphic presentation (",
"    <a class=\"graphic graphic_figure graphicRef55440 \" href=\"UTD.htm?38/28/39373\">",
"     figure 1",
"    </a>",
"    ) has been largely replaced in clinical practice by the flow-volume curve (",
"    <a class=\"graphic graphic_figure graphicRef75916 \" href=\"UTD.htm?7/5/7261\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58092 \" href=\"UTD.htm?35/47/36605\">",
"     figure 3",
"    </a>",
"    ), which provides a more immediate and intuitive perception of obstructive and restrictive disorders. However, the two graphic depictions are complementary and optimally should be analyzed together. Spirometry also includes the measurement of flow and volume with inspiration; however, inspiratory parameters are less commonly measured and are not discussed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Production of a reliable, sustained expiration requires coaching from the clinician and both coordination and focus on the part of the subject. Thus, spirometry is usually not obtainable predictably from children younger than six years.",
"   </p>",
"   <p>",
"    Spirometry is most useful for evaluation of common pediatric obstructive lung diseases, such as asthma, cystic fibrosis (CF), and the sequelae of bronchopulmonary dysplasia.",
"   </p>",
"   <p>",
"    The following discussion of spirometry focuses on the measured parameters, interpretation, and clinical applications most relevant to the primary care provider. Methodology and interpretation of spirometry in children are discussed in greater detail in guidelines published by the American Thoracic Society (ATS) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/3\">",
"     3",
"    </a>",
"    ] accessed through the ATS website at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Measured parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The important parameters derived from spirometry include indices of flow:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Forced expiratory volume in one second (FEV1)",
"     </li>",
"     <li>",
"      Flow between 25 and 75 percent of the vital capacity (FEF25-75), also known as the maximal midexpiratory flow rate (MMEFR)",
"     </li>",
"     <li>",
"      Peak expiratory flow rate (PEFR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These parameters also include indices of volume:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Forced vital capacity (FVC)",
"     </li>",
"     <li>",
"      Slow vital capacity (SVC) performed with a submaximal expiratory effort",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The air left in the lungs at the end of expiration (residual volume, RV) cannot be measured by spirometry. Thus, any lung capacity measurement that includes RV as a component cannot be derived by spirometry.",
"   </p>",
"   <p>",
"    The measured values for these parameters are compared to normative data and are reported as the percent of predicted value for subjects of similar age, height, gender, and race. Children with chronic conditions can also be monitored by comparing their measured values to those obtained at previous visits [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interpretation of spirometry depends upon which parameters are affected (",
"    <a class=\"graphic graphic_table graphicRef81072 \" href=\"UTD.htm?36/24/37260\">",
"     table 1",
"    </a>",
"    ). As a general rule, obstructive disorders affect indices of flow and restrictive disorders affect indices of volume.",
"   </p>",
"   <p>",
"    FEV1, FEF25-75%, and PEFR are decreased in obstructive disorders. FEF25-75 represents flow in smaller conducting airways. It is less effort-dependent than the other parameters, and it is a particularly useful measurement of milder intrathoracic airway obstruction. It can be reduced by 25 percent or more when the patient is symptom free",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    has a normal lung examination, and in the presence of normal FEV1 and PEFR [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/4\">",
"     4",
"    </a>",
"    ]. Such reduction in FEF25-75 can be visually noted as scooping of the flow-volume curve (",
"    <a class=\"graphic graphic_figure graphicRef58092 \" href=\"UTD.htm?35/47/36605\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    FVC typically is decreased in restrictive disorders, but may also be low due to gas trapping and hyperinflation in obstructive defects. In addition to affecting FVC, restrictive disorders can also lower parameters of flow. FEV1 is typically reduced, since the volume at the initiation of the expiratory maneuver is lower. Thus, a restrictive disorder should be considered when flow indices are lowered to a similar extent as the reduced FVC. A normal",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio of &gt;85 percent suggests that the observed decrease in flow is due to volume reduction rather than obstructed flow In this setting, additional measurements of lung volume using methods unavailable in the primary care setting should be undertaken to confirm the restrictive respiratory disorder. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Lung volume measurement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many children have both restrictive and obstructive abnormalities in lung functions. These patterns can be difficult to interpret. A reduced FVC out of proportion to the reduced",
"    <span class=\"nowrap\">",
"     FVC/FEV1",
"    </span>",
"    may indicate that an additional restrictive element exists. When in doubt, referral to a pulmonary function laboratory will be helpful.",
"   </p>",
"   <p>",
"    Faulty technique will yield unreliable results, and many children are unable to perform the maneuvers adequately. The two major parameters to follow are reproducibility of the flow-volume curve, and the duration of the expiratory maneuver. The latter is variable at young ages, but should always exceed one second and plateau for reliable interpretation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Flow-volume curve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flow-volume curve is a graphic representation of individual forced expiratory maneuvers. It is included in most spirometry reports; only the expiratory limb is typically displayed (",
"    <a class=\"graphic graphic_figure graphicRef75916 \" href=\"UTD.htm?7/5/7261\">",
"     figure 2",
"    </a>",
"    ). Obstructive defects are portrayed by scooping of the descending limb of the curve (",
"    <a class=\"graphic graphic_figure graphicRef58092 \" href=\"UTD.htm?35/47/36605\">",
"     figure 3",
"    </a>",
"    ), a change that can be easily detected by the experienced observer. The graphic display of the flow-volume curve also provides the best measure of quality control by permitting assessment of the reproducibility of repeated maneuvers. Reliable measurements should have at least three flow-volume curves that can be closely superimposed.",
"   </p>",
"   <p>",
"    Examination of the inspiratory flow-volume curve is helpful when flow obstruction derives from the extra-thoracic airways, most commonly in the larynx or upper trachea. These often useful parameters are not always included in the flow-volume curves reported by standard spirometers. Flow-volume patterns in upper airway obstruction are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4563009\">",
"    <span class=\"h2\">",
"     Use in asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care providers should consider the use of office spirometry in the evaluation and management of their patients with asthma. Spirometry can be used to support a diagnosis of asthma by demonstrating reversible airflow obstruction. This is particularly helpful in children with isolated symptoms (eg, persistent cough, exercise intolerance) or atypical presentations. In such patients, spirometry may also guide the clinician to an alternative diagnosis (eg, restrictive lung disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a diagnosis of an obstructive disorder has been made, the reversibility of the obstruction can be assessed by measuring FEV1 before and after inhalation of a bronchodilating agent (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    ). As a general rule, individuals without bronchial hyperreactivity have a &lt;5 percent increase in FEV1 after inhalation of a bronchodilator [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/5\">",
"     5",
"    </a>",
"    ]. A post-bronchodilator increase in FEV1 of &gt;12 percent constitutes a reversible obstructive lung defect and supports a diagnosis of asthma. The degree of reversible obstruction can vary from one visit to the next. Some children may have technically normal flows that are still less than 100 percent predicted. Bronchodilators can produce improvement in such children who may have flows of &gt;110 percent predicted as their normal values. A bronchodilator challenge in this circumstance may also produce enough improvement to confirm reversible airway obstruction and indicate asthma.",
"   </p>",
"   <p>",
"    Monitoring of asthma with spirometry, used in conjunction with daily symptoms and exacerbation frequency, is also useful in evaluating response to therapy and changes in asthma severity over time in children with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/6\">",
"     6",
"    </a>",
"    ]. Performance of spirometry at the start of treatment and during the first six months of follow-up were both associated with a decreased risk of hospitalization in the subsequent year in 27,193 Danish children aged 6 to 14 with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/7\">",
"     7",
"    </a>",
"    ]. Regular measurements in children with uncomplicated asthma are recommended by multiple asthma guidelines, such as the NAEPP and GINA guidelines.",
"   </p>",
"   <p>",
"    The mid-expiratory flows measure (FEF25-75), while highly variable in repeat measurements, is sometimes a sensitive parameter to indicate an obstructive defect, since it may be reduced in patients who are without symptoms and have normal FEV1 and PEFR [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barriers to performance of spirometry in the primary care setting include lack of time and training, particularly in interpretation of results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Peak expiratory flow rate (PEFR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PEFR measurement (often referred to as the peak flow measurement), unlike full spirometry, requires only a short expiratory blast without the subject having to sustain a prolonged expiratory effort and is, therefore, feasible for younger children four to six years of age. Typically, the highest of three PEFRs is reported. The portability and ease of use of inexpensive versions of the Wright Peak Flow Meter have made this device commonplace in the primary care setting and the home.",
"   </p>",
"   <p>",
"    PEFR meters are not \"the poor man's spirometer\" and have several important limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/4,9,10\">",
"     4,9,10",
"    </a>",
"    ]. The measurements obtained by PEFR meters are highly effort dependent and can be manipulated by children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, intrapersonal variability can be substantial and is particularly affected by circadian rhythms, although diurnal variability may also indicate poor control. Finally, because mini-PF meters are not precise tools, wide variation of recorded PEFR can be observed between devices, even of the same brand. Thus, measurements performed by devices other than those customarily used by the patient should be interpreted with caution.",
"   </p>",
"   <p>",
"    Peak flow meters have a limited role in establishing the diagnosis of asthma in the office. However, they are useful in gauging the severity of asthma exacerbations, both by comparing PEFR measurements to normative data (",
"    <a class=\"graphic graphic_table graphicRef64420 \" href=\"UTD.htm?1/12/1229\">",
"     table 2",
"    </a>",
"    ) and, more importantly, to preestablished baseline (\"personal best\") values. Such PEFR measurements are commonly used to assist in determining levels of interventions according to predetermined asthma management plans. The optional use of PEFR has also been incorporated into the NAEPP guidelines for asthma management [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/1\">",
"     1",
"    </a>",
"    ]. The use of PEFR monitoring in asthma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low-cost electronic hand-held spirometers that measure FEV1 and PEFR are now available for use in the home setting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The addition of FEV1, a more reliable spirometric parameter, to PEFR improves individual monitoring without significantly increasing cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bronchial challenge tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial challenge, or bronchoprovocation, tests are designed to provoke an asthmatic response in children suspected of having bronchial hyperreactivity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     Methacholine",
"    </a>",
"    , exercise,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cold air may be used as the challenge agent. Bronchial challenge tests are performed when there is uncertainty about the diagnosis of asthma. Exercise challenges are particularly useful to uncover exercise induced airway reactivity, a common and often underdiagnosed condition in childhood asthma. Bronchial challenge testing should be performed only in specialized centers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. In addition, because it has the potential to induce severe bronchospasm, bronchial challenge testing requires the presence of staff who are experienced in managing acute airway obstruction. Bronchial challenge tests are covered in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Spirometry in the care of cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;FEV1 is a key outcome measure in CF. It is routinely used to monitor the rate of progression of the lung disease, the need for interventions such as the administration of antibiotics or new drugs, and the effectiveness of such interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link&amp;anchor=H10#H10\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\", section on 'Pulmonary function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LUNG VOLUME MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung volume measurement is typically undertaken in specialized centers. The measurement of lung volumes is important in clinical conditions in which a restrictive lung defect",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    air trapping may be present. It is also important when addressing possible diffusion capacity defects. The partitioning of lung volumes is depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef55440 \" href=\"UTD.htm?38/28/39373\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diffusion capacity measurement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two conventional methods of measuring lung volumes in children: whole body plethysmography and gas dilution (usually with helium and, less frequently, by nitrogen washout). Both methods measure the functional residual capacity (FRC), which is the residual air in the lung at the end of exhalation during tidal breathing (",
"    <a class=\"graphic graphic_figure graphicRef55440 \" href=\"UTD.htm?38/28/39373\">",
"     figure 1",
"    </a>",
"    ). The thoracic gas volume measured equals FRC because the measurement is begun at end-expiration, after a stable baseline end-expiratory volume is achieved. The FRC is unobtainable by spirometry, since it includes the residual volume. The use of spirometry together with measures of FRC allows division of lung volumes, as depicted in the figure. Demonstration of reduced total lung capacity is the gold standard for the diagnosis of restrictive respiratory disease in both adults and children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Plethysmography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plethysmography involves placing the child inside a whole body plethysmograph or \"body box,\" a sealed structure similar in appearance to a telephone booth. This is typically done with the child alone, although the measurements can be performed with the child seated on the lap of a parent. The plethysmograph is tightly sealed, and the child is asked to breathe normally at tidal volume (TV) through a mouthpiece.",
"   </p>",
"   <p>",
"    The TV is measured, and the mouthpiece is briefly occluded by a shutter at end-expiration (FRC). With the child panting against the closed shutter, pressure oscillations are simultaneously measured at the mouthpiece and within the plethysmograph. This maneuver results in alternating compression and decompression of the intrathoracic gas, which is measured at the mouth and within the box. By employing Boyle's law, which states that the product of pressure and volume remains constant in a closed system (P1V1 = P2V2), the FRC is calculated.",
"   </p>",
"   <p>",
"    Plethysmography requires cooperation on the part of the subject and is, therefore, difficult to obtain in children younger than six years. Reliance on complex maneuvers such as panting against a closed shutter is the major limitation. In addition, some children find enclosure within the plethysmograph frightening.",
"   </p>",
"   <p>",
"    Plethysmography measures the total thoracic gas volume (TGV), including areas not communicating with the central airways (eg, cysts, areas distal to airway obstruction), while gas dilution measures only those areas of the lungs in direct communication with the measurement apparatus. Dilution techniques, therefore, will underestimate FRC in conditions in which there is significant air trapping. Thus, plethysmography is preferred in obstructive conditions, in which air trapping may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Gas dilution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gas dilution methods of lung volume determination are based upon the assessment of helium or nitrogen concentrations, and can be done either as a single breath measurement or, more commonly, with multiple breaths. The helium dilution method is more commonly used. Gas dilution methods require less cooperation from the child compared with plethysmography. These methods are a good alternative for patients who cannot physically fit in a plethysmograph (eg, children confined to wheelchairs) or those who feel too claustrophobic when sitting in the body box. Gas dilution using a sealed mask applied to the face can also be used in children whose buccal musculature is too weak to maintain a seal around a mouthpiece.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the multiple breath helium dilution method, the subject inhales a gas mixture containing a known concentration of helium in a known volume; the subject continues to inhale and exhale into a closed circuit until equilibrium is obtained. FRC is derived from the proportionate change of the helium concentration before and after equilibrium is reached (diluted by the gas inside the chest).",
"     </li>",
"     <li>",
"      Multiple breath nitrogen washout is performed via an open circuit measurement by having the child breathe 100 percent oxygen for several minutes until the nitrogen content of the exhalate is less than 1 percent, at which point virtually all the nitrogen in the lung has been exhaled into the spirometer. A rapid nitrogen analyzer measures the exhaled nitrogen in each exhalate as it is &ldquo;washed out&rdquo; with the 100 percent oxygen being inhaled. The volume of exhaled nitrogen is measured throughout the procedure. FRC can be calculated by dividing the total volume of nitrogen obtained by the difference in concentrations obtained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical application and interpretation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Restrictive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restrictive lung defects are defined by reduction in functional lung volumes and can only be confirmed by such measurements. In these conditions the TLC is reduced to below 80 percent of that predicted by age, height, and gender. The residual volume remains unchanged with hypotonia, or even increased in cases of chest wall disease. Thus, the",
"    <span class=\"nowrap\">",
"     RV/TLC",
"    </span>",
"    ratio is increased in children with these disorders, which mainly affect inspiratory, or vital capacity.",
"   </p>",
"   <p>",
"    The most common pathologic conditions in which lung volume determination is useful include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrinsic lung diseases, such as interstitial pneumonias",
"     </li>",
"     <li>",
"      Chest wall pathologies (eg, scoliosis)",
"     </li>",
"     <li>",
"      Neuromuscular diseases (eg, Duchenne muscular dystrophy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In restrictive defects caused by intrinsic pulmonary disease, the RV is often reduced as well, resulting in a normal",
"    <span class=\"nowrap\">",
"     RV/TLC",
"    </span>",
"    ratio. In restrictive lung defects caused by neuromuscular weakness and chest and spine deformities, the RV remains almost normal and the",
"    <span class=\"nowrap\">",
"     RV/TLC",
"    </span>",
"    ratio is increased (",
"    <a class=\"graphic graphic_table graphicRef81072 \" href=\"UTD.htm?36/24/37260\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Obstructive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung volume measurements are not needed to define obstructive defects, although such defects can lead to air trapping, defined as an increased",
"    <span class=\"nowrap\">",
"     RV/TLC",
"    </span>",
"    ratio in the setting of airway obstruction (a reduced",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio). When air trapping is present, the TLC can be normal or increased, the VC is normal or decreased, and the RV is increased. The latter changes can be the earliest parameters detected in early airway pathologies such as CF. Reduced VC,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symmetrically reduced VC and FEV1, should prompt lung volume measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFUSION CAPACITY MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffusion capacity is typically measured in specialized centers because of the cost and complexity of the required equipment. The diffusing capacity of the lungs for carbon monoxide (DLCO) and alveolar volume (VA) are measured in conditions in which impairment of gas diffusion across the alveolar-capillary membrane or a reduction in the alveolar-capillary surface area is suspected (eg, in children with exercise intolerance unrelated to bronchospasm, especially when associated with oxyhemoglobin desaturation, unexplained dyspnea or hypoxemia, known interstitial lung disease, or pulmonary fibrosis). The DLCO is used diagnostically to detect the presence of diffusion abnormalities when diseases of the pulmonary interstitium or vasculitis are suspected. It is used therapeutically to track effects of interventions for those diseases or side effects of therapies known to cause pulmonary fibrosis.",
"   </p>",
"   <p>",
"    DLCO and",
"    <span class=\"nowrap\">",
"     DLCO/VA",
"    </span>",
"    are reduced in intrinsic lung disease, such as the interstitial lung diseases and idiopathic pulmonary fibrosis as well as in pulmonary fibrosis secondary to cytotoxic or radiation therapy. Less frequently, pulmonary edema and pulmonary vascular diseases, including vasculitis associated with rheumatologic disease, can also reduce the DLCO. The DLCO is increased above the normal range in pulmonary hemorrhage. Diffusion capacity testing is not frequently performed in children; the technical complexity of its performance limits its use to the older child. The DLCO test is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RESPIRATORY MUSCLE PRESSURE MEASUREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determinations of respiratory muscle pressures are typically measured in specialized centers. These measurements evaluate the global strength of the inspiratory muscles (maximal inspiratory pressure, PImax) and expiratory muscles (maximal expiratory pressure, PEmax). The tests consist of a forceful inhalation and exhalation into tubing connected to a pressure manometer. The values obtained are compared to normative data for subjects of similar height, age, and gender.",
"   </p>",
"   <p>",
"    These tests are useful in determining whether decreases in expiratory flows or lung volumes are caused by weakness of various respiratory muscles. They are particularly valuable to assess progression of muscle weakness in children with progressive neuromuscular disorders such as Duchenne muscular dystrophy, since they can help determine when therapies such as assistance with coughing should be instituted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/17\">",
"     17",
"    </a>",
"    ]. These tests are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link\">",
"     \"Tests of respiratory muscle strength\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     EXHALED NITRIC OXIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In recent years, attention has focused on biomarkers that reflect pathologic processes such as airway inflammation. The most widely used of these measures is fractional exhaled nitric oxide (FeNO or eNO). Increased levels of this gas reflect the degree of eosinophilic airway inflammation in asthma and atopy. FeNO complements conventional lung function testing, and is being adopted by an increasing number of specialty clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/18\">",
"     18",
"    </a>",
"    ]. It can help identify patients with asthma who are most likely to respond to inhaled glucocorticoids, monitor poor adherence to glucocorticoid therapy, and help guide dosing of these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/19\">",
"     19",
"    </a>",
"    ]. FeNO measurement is easily performed, even in preschool age children. FeNO is not a reliable tool for assessing inflammation in cystic fibrosis. More portable and affordable instruments are being introduced, which will allow for more widespread and routine use. The measurement of FeNO and its role in the diagnosis and management of asthma is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=see_link\">",
"     \"Exhaled nitric oxide analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     EVALUATION OF PULMONARY FUNCTION IN EARLY CHILDHOOD AND INFANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry is usually difficult to obtain in children younger than six years of age. However, in one study, technically acceptable and reproducible spirometry was performed by experienced pediatric pulmonary function technicians in more than 80 percent of 307 children between the ages of three and six years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/20\">",
"     20",
"    </a>",
"    ]. Technical standards and reference data differ from those used for older children and adults; age-specific standards must be used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/21\">",
"     21",
"    </a>",
"    ]. In this young age group, FEV1 is often more than 95 percent of predicted. An alternative index to follow that is more sensitive is the forced expiratory volume at 0.5 seconds (FEV0.5). The advent of interactive software for incentive spirometry may facilitate performance of spirometry in preschool children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative measurements that require less patient cooperation have been developed for use in young children because of the difficulties in obtaining reliable forced expiratory maneuvers in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Of these, respiratory system resistance (Rrs) is the most commonly evaluated and can be assessed by whole body plethysmography, the interrupter technique (R[int]) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/21\">",
"     21",
"    </a>",
"    ], or the forced oscillation technique [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/21,25-27\">",
"     21,25-27",
"    </a>",
"    ]. None of these measurements are widely available. The uses and limitations of current techniques are reviewed in a statement by the American Thoracic Society (",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory morbidity is frequent in children younger than two years, making evaluation of pulmonary function all the more important in these children. Significant advances in the assessment of spirometry and plethysmography in this age group have been made since the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29112/abstract/28\">",
"     28",
"    </a>",
"    ]. These techniques, however, are beyond the scope of this review, since the need for sedation, expensive equipment, and a high level of training limits them to a few specialty centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8137017\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung function testing, including maximal respiratory pressures and lung volumes in patients who have known restrictive lung disease, and including spirometry in patients with chronic obstructive lung diseases such as CF, can help anticipate which patients may have a more difficult time with extubation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    require prolonged ventilatory assistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=see_link\">",
"       \"Patient information: Breathing tests (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4615583\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary function tests can measure obstructive, restrictive, and diffusion defects and respiratory muscle function. Measurements of flow and volume are most useful in the office setting. Spirometry, which provides both these measures, requires neither sophisticated technology nor expensive equipment, is easily interpreted, and is reliable when performed correctly. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The important parameters derived from spirometry include indices of flow, including forced expiratory volume in one second (FEV1), flow between 25 and 75 percent of the vital capacity (FEF25-75), also known as the maximal midexpiratory flow rate (MMEFR), and peak expiratory flow rate (PEFR) (",
"      <a class=\"graphic graphic_table graphicRef81072 \" href=\"UTD.htm?36/24/37260\">",
"       table 1",
"      </a>",
"      ). Indices of volume are also measured, including forced vital capacity (FVC). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Measured parameters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FEV1, FEF25-75, and PEFR are decreased in obstructive disorders. FVC typically is decreased in restrictive disorders and in obstructive diseases where air trapping is substantial. An",
"      <span class=\"nowrap\">",
"       FEV1/FVC",
"      </span>",
"      ratio &gt;85 percent suggests that the observed decrease in flow is due to volume reduction rather than airway obstruction and requires direct lung volume assessment for confirmation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spirometry can be used to support a diagnosis of asthma by demonstrating reversible airflow obstruction. Spirometry is also helpful in monitoring the response to long-term therapy and changes in the degree of obstruction over time. PEFR, as measured by a peak flow meter, may also be used to gauge the severity of asthma exacerbations, provided that caretakers and providers understand the limitations of peak flow meters (",
"      <a class=\"graphic graphic_table graphicRef64420 \" href=\"UTD.htm?1/12/1229\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4563009\">",
"       'Use in asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung volume measurement is typically undertaken in specialized centers. The measurement of lung volumes is important in clinical conditions in which a restrictive lung defect",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      air trapping may be present. It is also important when addressing possible diffusion capacity defects. There are two conventional methods of measuring lung volumes in children: whole body plethysmography and gas dilution. Both methods measure the functional residual capacity (FRC), which is the residual air in the lung at the end of exhalation during tidal breathing (",
"      <a class=\"graphic graphic_figure graphicRef55440 \" href=\"UTD.htm?38/28/39373\">",
"       figure 1",
"      </a>",
"      ). This value is unobtainable by spirometry. Restrictive lung defects are defined by reduction in functional lung volumes and can only be confirmed by such measurements. In these conditions the total lung capacity (TLC) is reduced to below 80 percent of that predicted by age, height, and gender. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Lung volume measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional types of pulmonary function tests that are typically performed at specialized centers include measurement of diffusing capacity of the lungs for carbon monoxide (DLCO), respiratory muscle pressure, and fractional exhaled nitric oxide. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diffusion capacity measurement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Respiratory muscle pressure measurements'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Exhaled nitric oxide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative measurements that require less patient cooperation have been developed for use in young children because of the difficulties in obtaining reliable forced expiratory maneuvers in this age group. Of these, respiratory system resistance (Rrs) is the most commonly evaluated and can be assessed by whole body plethysmography, the interrupter technique (R[int]), or the forced oscillation technique. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Evaluation of pulmonary function in early childhood and infancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     Hyatt RE, Scanlon PD, Nakamura M. Interpretation of pulmonary function tests. A practical guide., Lippincott, Williams &amp; Wilkins, Philadelphia 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/3\">",
"      Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/4\">",
"      Klein RB, Fritz GK, Yeung A, et al. Spirometric patterns in childhood asthma: peak flow compared with other indices. Pediatr Pulmonol 1995; 20:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/5\">",
"      Bouhuys A, Van de Woestijne KP. Mechanical consequences of airway smooth muscle relaxation. J Appl Physiol 1971; 30:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/6\">",
"      Nair SJ, Daigle KL, DeCuir P, et al. The influence of pulmonary function testing on the management of asthma in children. J Pediatr 2005; 147:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/7\">",
"      Moth G, Schiotz PO, Parner E, Vedsted P. Use of lung function tests in asthmatic children is associated with lower risk of hospitalization. A Danish population-based follow-up study. J Asthma 2010; 47:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/8\">",
"      Dombkowski KJ, Hassan F, Wasilevich EA, Clark SJ. Spirometry use among pediatric primary care physicians. Pediatrics 2010; 126:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/9\">",
"      Goldberg S, Springer C, Avital A, et al. Can peak expiratory flow measurements estimate small airway function in asthmatic children? Chest 2001; 120:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/10\">",
"      Yoos HL, Kitzman H, McMullen A, et al. Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring. Ann Allergy Asthma Immunol 2002; 88:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/11\">",
"      Colin A, Said E. How to cheat with the miniature wright peak flow meter. Chest 1984; 86:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/12\">",
"      Ezzahir N, Leske V, Peiffer C, Trang H. Relevance of a portable spirometer for detection of small airways obstruction. Pediatr Pulmonol 2005; 39:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/13\">",
"      Bastian-Lee Y, Chavasse R, Richter H, Seddon P. Assessment of a low-cost home monitoring spirometer for children. Pediatr Pulmonol 2002; 33:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/14\">",
"      Mortimer KM, Fallot A, Balmes JR, Tager IB. Evaluating the use of a portable spirometer in a study of pediatric asthma. Chest 2003; 123:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/15\">",
"      Korhonen H, Remes ST, Kannisto S, Korppi M. Hand-held turbine spirometer: agreement with the conventional spirometer at baseline and after exercise. Pediatr Allergy Immunol 2005; 16:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/16\">",
"      Pfaff JK, Morgan WJ. Pulmonary function in infants and children. Pediatr Clin North Am 1994; 41:401.",
"     </a>",
"    </li>",
"    <li>",
"     Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004; 170:456. ajrccm.atsjournals.org/cgi/content/full/170/4/456 (Accessed on September 14, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/18\">",
"      Pijnenburg MW, De Jongste JC. Exhaled nitric oxide in childhood asthma: a review. Clin Exp Allergy 2008; 38:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/19\">",
"      Kercsmar C. Exhaled nitric oxide in the diagnosis and management of childhood asthma. Ther Adv Respir Dis 2010; 4:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/20\">",
"      Eigen H, Bieler H, Grant D, et al. Spirometric pulmonary function in healthy preschool children. Am J Respir Crit Care Med 2001; 163:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/21\">",
"      Beydon N, Davis SD, Lombardi E, et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med 2007; 175:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/22\">",
"      Vilozni D, Barker M, Jellouschek H, et al. An interactive computer-animated system (SpiroGame) facilitates spirometry in preschool children. Am J Respir Crit Care Med 2001; 164:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/23\">",
"      Beydon N. Pulmonary function testing in young children. Paediatr Respir Rev 2009; 10:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/24\">",
"      Gangell CL, Hall GL, Stick SM, et al. Lung function testing in preschool-aged children with cystic fibrosis in the clinical setting. Pediatr Pulmonol 2010; 45:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/25\">",
"      Kalhoff H, Breidenbach R, Smith HJ, Marek W. Impulse oscillometry in preschool children and association with body mass index. Respirology 2011; 16:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/26\">",
"      Delacourt C, Lorino H, Fuhrman C, et al. Comparison of the forced oscillation technique and the interrupter technique for assessing airway obstruction and its reversibility in children. Am J Respir Crit Care Med 2001; 164:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/27\">",
"      Hall GL, Sly PD, Fukushima T, et al. Respiratory function in healthy young children using forced oscillations. Thorax 2007; 62:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29112/abstract/28\">",
"      Colin AA. Infant pulmonary testing -- techniques, physiological perspectives and clinical applications. Paediatr Respir Rev 2004; 5 Suppl A:S73.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5735 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29112=[""].join("\n");
var outline_f28_27_29112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4615583\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SPIROMETRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Measured parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Flow-volume curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4563009\">",
"      Use in asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Peak expiratory flow rate (PEFR)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bronchial challenge tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Spirometry in the care of cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LUNG VOLUME MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Plethysmography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Gas dilution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical application and interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Restrictive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Obstructive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFUSION CAPACITY MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RESPIRATORY MUSCLE PRESSURE MEASUREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      EXHALED NITRIC OXIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      EVALUATION OF PULMONARY FUNCTION IN EARLY CHILDHOOD AND INFANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8137017\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4615583\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5735|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/28/39373\" title=\"figure 1\">",
"      Lung volume and capacities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/5/7261\" title=\"figure 2\">",
"      Normal flow volume curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/47/36605\" title=\"figure 3\">",
"      Obstructive flow volume curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5735|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/24/37260\" title=\"table 1\">",
"      PFT interpretation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/12/1229\" title=\"table 2\">",
"      PEFR in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=related_link\">",
"      Exhaled nitric oxide analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43513?source=related_link\">",
"      Overview of aerobic exercise testing in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=related_link\">",
"      Patient information: Breathing tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=related_link\">",
"      Tests of respiratory muscle strength",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_27_29113="Digoxin: Drug information";
var content_f28_27_29113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Digoxin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/34/30245?source=see_link\">",
"    see \"Digoxin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"    see \"Digoxin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lanoxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Digoxin&reg;;",
"     </li>",
"     <li>",
"      Digoxin Injection CSD;",
"     </li>",
"     <li>",
"      Lanoxin&reg;;",
"     </li>",
"     <li>",
"      Pediatric Digoxin CSD;",
"     </li>",
"     <li>",
"      PMS-Digoxin;",
"     </li>",
"     <li>",
"      Toloxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F160189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Cardiac Glycoside",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F160147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     When changing from oral (tablets or liquid) or I.M. to I.V. therapy, dosage should be reduced by 20% to 25%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation (rate control) in patients with heart failure:",
"     </b>",
"     Loading dose:  I.V.: 0.25 mg every 2 hours, up to 1.5 mg within 24 hours; for nonacute situations, may administer 0.5 mg orally once daily for 2 days followed by oral maintenance dose. Maintenance dose: I.V., Oral: 0.125-0.375 mg once daily (Fuster, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Daily maintenance dose (",
"     <b>",
"      Note:",
"     </b>",
"     Loading dose not recommended): Oral: 0.125-0.25 mg once daily; higher daily doses (up to 0.5 mg/day) are rarely necessary. If patient is &gt;70 years of age, has impaired renal function, or has a low lean body mass, low doses (eg, 0.125 mg daily or every other day) should be used (Hunt, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Supraventricular tachyarrhythmias (rate control):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     Total digitalizing dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Oral: 0.75-1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     I.V., I.M.: 0.5-1 mg (",
"     <b>",
"      Note:",
"     </b>",
"     I.M. not preferred due to severe injection site pain.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Give",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     (one-half) of the total digitalizing dose (TDD) as the initial dose, then give",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     (one-quarter) of the TDD in each of 2 subsequent doses at 6- to 8-hour intervals. Obtain ECG 6 hours after each dose to assess potential toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Daily maintenance dose:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Oral: 0.125-0.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     I.V., I.M.: 0.1-0.4 mg once daily (",
"     <b>",
"      Note:",
"     </b>",
"     I.M. not preferred due to severe injection site pain.)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F160169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"      see \"Digoxin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Atrial dysrhythmias (rate control), HF:",
"     </b>",
"     When changing from oral (tablets or liquid) or I.M. to I.V. therapy, dosage should be reduced by 20% to 25%. See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Dosage Recommendations for Digoxin",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col align=\"left\" width=\"110\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"90\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Total Digitalizing Dose",
"         <sup>",
"          2,3",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/kg)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Daily Maintenance Dose",
"         <sup>",
"          3,4",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/kg)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Oral",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         I.V. or I.M.",
"         <sup>",
"          5",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Oral",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         I.V. or I.M.",
"         <sup>",
"          5",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         <b>",
"          Heart failure:",
"         </b>",
"         A lower serum digoxin concentration may be adequate to treat heart failure (compared to cardiac arrhythmias); consider doses at the lower end of the recommended range for treatment of heart failure; a digitalizing dose (loading dose) may not be necessary when treating heart failure (Ross, 2001).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         <b>",
"          Do not give full total digitalizing dose (TDD) at once.",
"         </b>",
"         Give one-half of the total digitalizing dose (TDD) in the initial dose, then give one-quarter of the TDD in each of two subsequent doses at 6- to 8-hour intervals. Obtain ECG 6 hours after each dose to assess potential toxicity.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Based on lean body weight and normal renal function for age. Decrease dose in patients with decreased renal function; digitalizing dose often not recommended in infants and children.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Divided every 12 hours in infants and children &lt;10 years of age. Given once daily to children &gt;10 years of age and adults.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          5",
"         </sup>",
"         I.M. not preferred due to severe injection site pain. If I.M. route is necessary, administer as deep injection followed by massage of injection site.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Preterm infant",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-7.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Full-term infant",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25-35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1 mo - 2 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.5-12",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         2-5 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25-35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.5-10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5-10 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;10 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F160148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose is based on assessment of lean body mass and renal function. Elderly patients with low lean body mass may experience higher digoxin concentrations due to reduced volume of distribution (Cheng, 2010). Decrease dose in patients with decreased renal function (see Dosing in Renal Impairment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     If patient is &gt;70 years of age, low doses (eg, 0.125 mg daily or every other day) should be used (Hunt, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F160149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Loading dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ESRD: If loading dose necessary, reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute renal failure: Based on expert opinion, if patient in acute renal failure requires ventricular rate control (eg, in atrial fibrillation), consider alternative therapy. If loading digoxin becomes necessary, patient volume of distribution may be increased and reduction in loading dose may not be necessary; however, maintenance dosing will require adjustment as long as renal failure persists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 25% to 75% of dose or every 36 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 10% to 25% of dose or every 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 250 mcg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanoxin&reg;: 250 mcg/mL (2 mL) [contains ethanol 10%, propylene glycol 40%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [pediatric]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanoxin&reg;: 100 mcg/mL (1 mL) [contains ethanol 10%, propylene glycol 40%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 50 mcg/mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 125 mcg, 250 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanoxin&reg;: 125 mcg, 250 mcg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apo-Digoxin&reg;: 62.5 mcg, 125 mcg, 250 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: I.V. route preferred. If I.M. injection necessary, administer by deep injection followed by massage at the injection site. Inject no more than 2 mL per injection site. May cause intense pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: May be administered undiluted or diluted. Inject slowly over &ge;5 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F160196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS with KCl 20 mEq, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, and NS. May be diluted fourfold in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or SWFI for direct injection (or may be administered undiluted).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin, bivalirudin, ciprofloxacin, cisatracurium, dexmedetomidine, diltiazem, doripenem, famotidine, fenoldopam, fentanyl, heparin, heparin with hydrocortisone sodium succinate, hetastarch in lactate electrolyte injection (Hextend&reg;), inamrinone, linezolid, meperidine, meropenem, midazolam, milrinone, morphine, nesiritide, potassium chloride, remifentanil, tacrolimus, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amiodarone, amphotericin B cholesteryl sulfate complex, fluconazole, foscarnet, pantoprazole, telavancin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Insulin (regular), propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, heparin, hydralazine, milrinone.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F160120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate (or stage C as recommended by the ACCF/AHA) heart failure (HF); atrial fibrillation (rate-control)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In treatment of atrial fibrillation (AF), use is not considered first-line unless AF coexistent with heart failure or in sedentary patients (Fuster, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9729169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal tachycardia with or without hydrops; to slow ventricular rate in supraventricular tachyarrhythmias such as supraventricular tachycardia (SVT) excluding atrioventricular reciprocating tachycardia (AVRT)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F160198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Digoxin may be confused with Desoxyn&reg;, doxepin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lanoxin&reg; may be confused with Lasix&reg;, levothyroxine, Levoxyl&reg;, Levsinex&reg;, Lomotil&reg;, Mefoxin&reg;, naloxone, Xanax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lanoxin [U.S., Canada, and multiple international markets] may be confused with Limoxin brand name for ambroxol [Indonesia] and amoxicillin [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incidence not always reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Accelerated junctional rhythm, asystole, atrial tachycardia with or without block, AV dissociation, first-, second- (Wenckebach), or third-degree heart block, facial edema, PR prolongation, PVCs (especially bigeminy or trigeminy), ST segment depression, ventricular tachycardia or ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness (6%), mental disturbances (5%), headache (4%), apathy, anxiety, confusion, delirium, depression, fever, hallucinations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash (erythematous, maculopapular [most common], papular, scarlatiniform, vesicular or bullous), pruritus, urticaria, angioneurotic edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4%), vomiting (2%), diarrhea (4%), abdominal pain, anorexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances (blurred or yellow vision)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Laryngeal edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Asymmetric chorea, gynecomastia, thrombocytopenia, palpitation, intestinal ischemia, hemorrhagic necrosis of the intestines, vaginal cornification, eosinophilia, sexual dysfunction, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F160123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to digoxin (rare) or other forms of digitalis, or any component of the formulation; ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F160105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects: Monitor for proarrhythmic effects (especially with digoxin toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Accessory bypass tract (eg, Wolff-Parkinson-White [WPW] syndrome): During an episode of atrial fibrillation or flutter in patients with an accessory bypass tract, use has been associated with increased anterograde conduction down the accessory pathway leading to ventricular fibrillation; avoid use in such patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute MI: Use with caution in patients with an acute MI (within 6 months); may increase myocardial oxygen demand. During the immediate post-MI period, digoxin administered I.V. may be used in the acute treatment of refractory atrial fibrillation/flutter (especially when HF or LV dysfunction coexists) or refractory re-entrant PSVT (Antman, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrioventricular (AV) block: Avoid use in patients with second- or third-degree heart block (except in patients with a functioning artificial pacemaker); incomplete AV block (eg, Stokes-Adams attacks) may progress to complete block with digoxin administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Beri beri heart disease: Patients with beri beri heart disease may fail to adequately respond to digoxin therapy; treat underlying thiamine deficiency concomitantly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy; toxicity may occur despite therapeutic digoxin concentrations (eg, &lt;2 ng/mL). Hypercalcemia may increase the risk of digoxin toxicity; maintain normocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): HF patients with preserved left ventricular function including patients with restrictive cardiomyopathy, constrictive pericarditis, and amyloid heart disease may be susceptible to digoxin toxicity; avoid use unless used to control ventricular response with atrial fibrillation. Digoxin should not be used in patients with low EF, sinus rhythm, and no HF symptoms since the risk of harm may be greater than clinical benefit (Hunt, 2009). Withdrawal of digoxin in clinically stable patients with HF may lead to recurrence of HF symptoms (Packer, 1993).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypermetabolic states: Atrial arrhythmias associated with hypermetabolic states are very difficult to treat; treat underlying condition first. If digoxin is used, ensure digoxin toxicity does not occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Outflow obstruction may worsen due to the positive inotropic effects of digoxin; avoid use unless used to control ventricular response with atrial fibrillation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sinus nodal disease: Use with caution in patients with sinus nodal disease (eg, sick sinus syndrome); may worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with hypothyroidism, higher digoxin concentrations may result. Use with caution in patients with hyperthyroidism, lower digoxin concentrations may result due to decreased absorption.",
"     <b>",
"      Note:",
"     </b>",
"     New-onset atrial fibrillation or exacerbation of ventricular arrhythmias should prompt evaluation of thyroid status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium: Avoid rapid I.V. administration of calcium in digitalized patients; may produce serious arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use caution in patients taking strong inducers or inhibitors of P-glycoprotein (eg, cyclosporine). Upon initiation of amiodarone, propafenone, quinidine, or verapamil the need for digoxin should be evaluated and the digoxin dose should be reduced (eg, by 50%) to avoid toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; decreases in renal clearance may result in toxic effects; in general, avoid doses &gt;0.125 mg/day; in heart failure, higher doses may increase the risk of potential toxicity and have not been shown to provide additional benefit (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elective electrical cardioversion: It is not necessary to routinely reduce or hold digoxin therapy prior to elective electrical cardioversion for atrial fibrillation; however, exclusion of digoxin toxicity (eg, clinical and ECG signs) is necessary prior to cardioversion. If signs of digoxin excess exist, withhold digoxin and delay cardioversion until toxicity subsides; usually &gt;24 hours (Fuster, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F160185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: May decrease the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Digoxin may enhance the adverse/toxic effect of Adenosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic, Oral Inhalation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents: May decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Alitretinoin; Altretamine; Aminoglutethimide; Anastrozole; Asparaginase (E. coli); Asparaginase (Erwinia); AzaCITIDine; Busulfan; Capecitabine; CARBOplatin; Chlorambucil; CISplatin; Cladribine; Cytarabine (Liposomal); Dacarbazine; DACTINomycin; DAUNOrubicin (Conventional); DAUNOrubicin (Liposomal); Denileukin Diftitox; DOCEtaxel; EPIrubicin; Estramustine; Etoposide; Etoposide Phosphate; Exemestane; Fludarabine; Fluorouracil (Systemic); Fluorouracil (Topical); Gemcitabine; Goserelin; Hydroxyurea; IDArubicin; Ifosfamide; Irinotecan; Letrozole; Leuprolide; Lomustine; Mechlorethamine; Megestrol; Mercaptopurine; MitoMYcin (Systemic); Mitotane; MitoXANtrone; Nilutamide; PACLitaxel; Pegaspargase; Pentostatin; Polyestradiol; Porfimer; RiTUXimab; Streptozocin; Tamoxifen; Temozolomide; Teniposide; Thioguanine; Thiotepa; Topotecan; Toremifene; Tretinoin (Systemic); Valrubicin; VinBLAStine; Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Anthracycline, Systemic): Cardiac Glycosides may diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antithyroid Agents: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the bradycardic effect of Cardiac Glycosides.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Cardiac Glycosides.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Colesevelam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Digoxin. Management: In patients initiating digoxin during boceprevir treatment, initiate at the lowest possible digoxin dose, monitor serum digoxin concentrations, and titrate carefully due to a possible risk of elevated digoxin concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: Digoxin may enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloNIDine: May enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: Digoxin may increase the serum concentration of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: Digoxin may enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin.  Management: Avoid concurrent use of digoxin when possible.  If concurrent use is necessary, reduce adult digoxin dose by 50%,  monitor digoxin concentration closely, and increase monitoring for both clinical response to therapy and the occurrence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Digoxin. Management: Monitor serum digoxin concentrations and adjust dose as needed. In patients initiating a regimen of digoxin with etravirine, digoxin should be initiated at the lowest dose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of Digoxin. This effect is specific to digoxin administered as slow dissolution oral tablets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Cardiac Glycosides. Management: Consider preemptive cardiac glycoside dose adjustments with initiation / changes / discontinuation of itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kaolin: May decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lenalidomide: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Cardiac Glycosides. This by increasing the risk of hypokalemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Cardiac Glycosides.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Cardiac Glycosides may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Digoxin. Management: Measure serum digoxin concentration 1-2 weeks following mifepristone initiation, and in accordance with normal clinical practice thereafter, adjusting dose as needed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Milnacipran: May enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased, particularly with IV digoxin. Management: Avoid concurrent use of intravenous (IV) digoxin in patients receiving milnacipran. Use caution when using oral digoxin and milnacipran together, monitoring closely for possible postural hypotension and tachycardia.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: May increase the serum concentration of Digoxin. Management: Consider using the lowest dose of digoxin when initiating concurrent mirabegron.  Monitor serum digoxin concentrations closely to help guide digoxin dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: May enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: May enhance the adverse/toxic effect of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: May decrease the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Cardiac Glycosides. Management: Upon quinidine initiation, consider reducing cardiac glycoside dose by 25% to 50%, with continued monitoring of glycoside serum concentrations and clinical response until the quinidine reaches steady state (5-10 days).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the adverse/toxic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SitaGLIPtin: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin. Management: Administer digoxin at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Digoxin. Management: Use the lowest possible digoxin dose when starting therapy in a patient who is being treated with telaprevir, and monitor clinical response and serum concentrations closely for further dosing adjustments.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telmisartan: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F160139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Digoxin peak serum concentrations may be decreased if taken with food. Meals containing increased fiber (bran) or foods high in pectin may decrease oral absorption of digoxin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid ephedra (risk of cardiac stimulation). Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9729170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Digoxin crosses the placenta and can be detected in the fetus. Digoxin is recommended as first-line in the treatment of fetal tachycardia determined to be SVT. In pregnant women with atrial fibrillation or SVT, use of digoxin is recommended (Class I recommendation; Blomstr&ouml;m-Lundqvist, 2003; Fuster, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F160153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9729172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Digoxin is excreted into breast milk and similar concentrations are found within mother's serum and milk. The manufacturer recommends that caution be used in nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F160126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain adequate amounts of potassium in diet to decrease risk of hypokalemia (hypokalemia may increase risk of digoxin toxicity).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F160125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Digoxin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/mL (2 mL): $2.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Digoxin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/mL (60 mL): $42.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lanoxin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/mL (1 mL): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/mL (2 mL): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Digoxin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.125 mg (100): $27.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $27.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lanoxin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.125 mg (1000): $759.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $76.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F160114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Heart rate and rhythm should be monitored along with periodic ECGs to assess desired effects and signs of toxicity; baseline and periodic serum creatinine. Periodically monitor serum potassium, magnesium, and calcium especially if on medications where these electrolyte disturbances can occur (eg, diuretics), or if patient has a history of hypokalemia or hypomagnesemia. Observe patients for noncardiac signs of toxicity, confusion, and depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     When to draw serum digoxin concentrations: Digoxin serum concentrations are monitored because digoxin possesses a narrow therapeutic serum range; the therapeutic endpoint is difficult to quantify and digoxin toxicity may be life-threatening. Digoxin serum concentrations should be drawn",
"     <b>",
"      at least 6-8 hours after last dose, regardless of route of administration (optimally 12-24 hours after a dose). Note:",
"     </b>",
"     Serum digoxin concentrations may decrease in response to exercise due to increased skeletal muscle uptake; a period of rest (eg, ~2 hours) after exercise may be necessary prior to drawing serum digoxin concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Initiation of therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      If a loading dose is given:",
"     </b>",
"     Digoxin serum concentration may be drawn within 12-24 hours after the initial loading dose administration. Concentrations drawn this early may confirm the relationship of digoxin plasma concentrations and response but are of little value in determining maintenance doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      If a loading dose is not given:",
"     </b>",
"     Digoxin serum concentration should be obtained after 3-5 days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Trough",
"     </b>",
"     concentrations should be followed just prior to the next dose or at a minimum of 6-8 hours after last dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Digoxin serum concentrations should be obtained within 5-7 days (approximate time to steady-state) after any dosage changes. Continue to obtain digoxin serum concentrations 7-14 days after any change in maintenance dose.",
"     <b>",
"      Note:",
"     </b>",
"     In patients with end-stage renal disease, it may take 15-20 days to reach steady-state.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients who are receiving electrolyte-depleting medications such as diuretics, serum potassium, magnesium, and calcium should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Digoxin serum concentrations should be obtained whenever any of the following conditions occur:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Questionable patient compliance or to evaluate clinical deterioration following an initial good response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Changing renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suspected digoxin toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initiation or discontinuation of therapy with drugs (eg, amiodarone, quinidine, verapamil) which potentially interact with digoxin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Any disease changes (eg, thyroid disease)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F160117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Digoxin therapeutic serum concentrations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heart failure: 0.5-0.8 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adults: &lt;0.5 ng/mL; probably indicates underdigitalization unless there are special circumstances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxic: &gt;2 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Digoxin-like immunoreactive substance (DLIS) may cross-react with digoxin immunoassay. DLIS has been found in patients with renal and liver disease, heart failure, neonates, and pregnant women (3rd trimester).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F160127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cadef Elixir Pediatric (KP);",
"     </li>",
"     <li>",
"      Cardiacin (TW);",
"     </li>",
"     <li>",
"      Cardiogoxin (AR);",
"     </li>",
"     <li>",
"      Cardioxin (PH);",
"     </li>",
"     <li>",
"      Cardoxin (IL);",
"     </li>",
"     <li>",
"      Digosin (JP, KP);",
"     </li>",
"     <li>",
"      Digoxin (PL);",
"     </li>",
"     <li>",
"      Digoxin NI (ID);",
"     </li>",
"     <li>",
"      Digoxin &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Digoxin-Sandoz (BF, BJ, CH, CI, ET, GH, GM, GN, ID, JP, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Digoxin-Zori (IL);",
"     </li>",
"     <li>",
"      Digoxina (CO, ES, GT, HN, NI, PE);",
"     </li>",
"     <li>",
"      Digoxina Boehringer (ES);",
"     </li>",
"     <li>",
"      Digoxine Nativelle (LU);",
"     </li>",
"     <li>",
"      Digoxine Navtivelle (FR);",
"     </li>",
"     <li>",
"      Dilacor (BG);",
"     </li>",
"     <li>",
"      Dilanacin (CY, EG, IQ, JO, SD);",
"     </li>",
"     <li>",
"      Eudigox (IT);",
"     </li>",
"     <li>",
"      Fargoxin (ID);",
"     </li>",
"     <li>",
"      Grexin (TH);",
"     </li>",
"     <li>",
"      Ke Li (CL);",
"     </li>",
"     <li>",
"      Lanacordin (ES);",
"     </li>",
"     <li>",
"      Lanicor (AE, AR, AT, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, CZ, DE, EC, EG, ET, GH, GM, GN, GR, GY, HR, IQ, IR, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Lanikor (RU);",
"     </li>",
"     <li>",
"      Lanox (PH);",
"     </li>",
"     <li>",
"      Lanoxin (AE, AR, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CI, CY, EG, ET, GB, GH, GM, GN, GR, GY, HK, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PH, PK, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, UY, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Lanoxin PG (NZ);",
"     </li>",
"     <li>",
"      Lenoxin (DE);",
"     </li>",
"     <li>",
"      Mapluxin (MX);",
"     </li>",
"     <li>",
"      Purgoxin (ZA);",
"     </li>",
"     <li>",
"      Sigmaxin (AU);",
"     </li>",
"     <li>",
"      Toloxin (TH);",
"     </li>",
"     <li>",
"      Vidaxil (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F160104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Heart failure: Inhibition of the sodium/potassium ATPase pump in myocardial cells results in a transient increase of  intracellular sodium, which in turn promotes calcium influx via the sodium-calcium exchange pump leading to increased contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Supraventricular arrhythmias: Direct suppression of the AV node conduction to increase effective refractory period and decrease conduction velocity - positive inotropic effect, enhanced vagal tone, and decreased ventricular rate to fast atrial arrhythmias. Atrial fibrillation may decrease sensitivity and increase tolerance to higher serum digoxin concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F160122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Heart rate control: Oral: 1-2 hours; I.V.: 5-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Heart rate control: Oral: 2-8 hours; I.V.: 1-6 hours;",
"     <b>",
"      Note:",
"     </b>",
"     In patients with atrial fibrillation, median time to ventricular rate control in one study was 6 hours (range: 3-15 hours) (Siu, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Adults: 3-4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: By passive nonsaturable diffusion in the upper small intestine; food may delay, but does not affect extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal renal function: 6-7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Extensive to peripheral tissues, with a distinct distribution phase which lasts 6-8 hours; concentrates in heart, liver, kidney, skeletal muscle, and intestines. Heart/serum concentration is 70:1. Pharmacologic effects are delayed and do not correlate well with serum concentrations during distribution phase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyperthyroidism: Increased V",
"     <sub>",
"      d",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyperkalemia, hyponatremia: Decreased digoxin distribution to heart and muscle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypokalemia: Increased digoxin distribution to heart and muscles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concomitant quinidine therapy: Decreased V",
"     <sub>",
"      d",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic renal failure: 4-6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Decreased sodium/potassium ATPase activity - decreased tissue binding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates, full-term: 7.5-10 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 16 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 7 L/kg, decreased with renal disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~25%; in uremic patients, digoxin is displaced from plasma protein binding sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via sequential sugar hydrolysis in the stomach or by reduction of lactone ring by intestinal bacteria (in ~10% of population, gut bacteria may metabolize up to 40% of digoxin dose); once absorbed, only ~16% is metabolized to 3-beta-digoxigenin, 3-keto-digoxigenin, and glucuronide and sulfate conjugates; metabolites may contribute to therapeutic and toxic effects of digoxin; metabolism is reduced with decompensated HF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral (formulation dependent): Elixir: 70% to 85%; Tablet: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (age, renal and cardiac function dependent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: Premature: 61-170 hours; Full-term: 35-45 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 18-25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 18-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 36-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, anephric: 3.5-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: 38 hours; Metabolites: Digoxigenin: 4 hours; Monodigitoxoside: 3-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50% to 70% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(15):1871-909.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/14557344/pubmed\" id=\"14557344\" target=\"_blank\">",
"        14557344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheng JW and Rybak I, &ldquo;Use of Digoxin for Heart Failure and Atrial Fibrillation in Elderly Patients,&rdquo;",
"      <i>",
"       Am J Geriatr Pharmacother",
"      </i>",
"      , 2010, 8(5):419-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/21335295/pubmed\" id=\"21335295\" target=\"_blank\">",
"        21335295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falk RH, Knowlton AA, Bernard SA, et al, &ldquo;Digoxin for Converting Recent-Onset Atrial Fibrillation to Sinus Rhythm, A Randomized, Double-Blinded Trial,&rdquo;",
"      <i>",
"       Ann Int Med",
"      </i>",
"      , 1987, 106(4):503-6",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/3548521/pubmed\" id=\"3548521\" target=\"_blank\">",
"        3548521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Intravenous Digoxin in Acute Atrial Fibrillation. Results of a Randomized, Placebo-Controlled Multicentre Trial in 239 Patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1997, 18(4):649-54",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/9129897/pubmed\" id=\"9129897\" target=\"_blank\">",
"        9129897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jordaens L, Trouerbach J, Calle P, et al, &ldquo;Conversion of Atrial Fibrillation to Sinus Rhythm and Rate Control by Digoxin in Comparison to Placebo,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1997, 18(4):643-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/9129896/pubmed\" id=\"9129896\" target=\"_blank\">",
"        9129896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murgatroyd FD, Gibson SM, Baiyan X, et al, &ldquo;Double-Blind Placebo-Controlled Trial of Digoxin in Symptomatic Paroxysmal Atrial Fibrillation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(21):2765-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/10351970/pubmed\" id=\"10351970\" target=\"_blank\">",
"        10351970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Gheorghiade M, Young JB, et al, &ldquo;Withdrawal of Digoxin From Patients With Chronic Heart Failure Treated With Angiotensin-converting Enzyme Inhibitors, RADIANCE Study,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(1):1-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/8505940/pubmed\" id=\"8505940\" target=\"_blank\">",
"        8505940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathore SS, Curtis JP, Wang Y, et al, &ldquo;Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(7):871-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/12588271/pubmed\" id=\"12588271\" target=\"_blank\">",
"        12588271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts SA, Diaz C, Nolan PE, et al, &ldquo;Effectiveness and Costs of Digoxin Treatment for Atrial Fibrillation and Flutter,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1993, 72(7):567-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/8362772/pubmed\" id=\"8362772\" target=\"_blank\">",
"        8362772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenthal D, Chrisant MR, Edens E, et al, &ldquo;International Society for Heart and Lung Transplantation: Practice Guidelines for Management of Heart Failure in Children,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2004, 23(12):1313-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/15607659/pubmed\" id=\"15607659\" target=\"_blank\">",
"        15607659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siu CW, Lau CP, Lee WL, et al, &ldquo;Intravenous Diltiazem is Superior to Intravenous Amiodarone or Digoxin for Achieving Ventricular Rate Control in Patients With Acute Uncomplicated Atrial Fibrillation,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(7):2174-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/19487941/pubmed\" id=\"19487941\" target=\"_blank\">",
"        19487941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;The Effect of Digoxin on Mortality and Morbidity in Patients With Heart Failure. The Digitalis Investigation Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(8):525-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/9036306/pubmed\" id=\"9036306\" target=\"_blank\">",
"        9036306",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ujhelyi MR and Robert S, &ldquo;Pharmacokinetic Aspects of Digoxin-Specific Fab Therapy in the Management of Digitalis Toxicity,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(6):483-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/7656506/pubmed\" id=\"7656506\" target=\"_blank\">",
"        7656506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/27/29113/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9360 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29113=[""].join("\n");
var outline_f28_27_29113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160142\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160143\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160189\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160147\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160169\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160148\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160149\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796078\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160116\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950035\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160101\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803126\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160196\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160120\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729169\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160198\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160187\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160123\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160105\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160185\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160110\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160139\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160112\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729170\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160153\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729172\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160126\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160125\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160114\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160117\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160127\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160104\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160122\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9360\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9360|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/34/30245?source=related_link\">",
"      Digoxin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=related_link\">",
"      Digoxin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_27_29114="Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula";
var content_f28_27_29114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/27/29114/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29114/contributors\">",
"     Christopher M Oermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/27/29114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29114/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/27/29114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/27/29114/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/27/29114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies of the respiratory tract include malformations located anywhere from the nose to the alveoli. Anomalies of the intrathoracic airways, including the trachea, bronchi, and lower airways, are reviewed here. Disorders of the upper respiratory tract are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=see_link\">",
"     \"Congenital anomalies of the nose\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=see_link\">",
"     \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRACHEAL ATRESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal atresia, also known as agenesis or aplasia of the trachea, is a rare, usually lethal disorder. The defect consists of partial or complete absence of the trachea below the larynx. The lower respiratory tract often is connected to the gastrointestinal tract via a distal tracheo- or bronchoesophageal fistula. Lack of a fistula between the airway and esophagus is incompatible with life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tracheal atresia is classified based upon the presence and extent of the tracheal remnant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Several classification systems have been proposed; the most widely applied recognizes three distinct lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type I &ndash; a short segment of trachea connects to the anterior esophagus",
"     </li>",
"     <li>",
"      Type II &ndash; the airway and esophagus are fused at the level of the carina, with no tracheal remnant",
"     </li>",
"     <li>",
"      Type III &ndash; Right and left mainstem bronchi directly adjoin the esophagus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with many of the congenital malformations of the respiratory tract, tracheal atresia may be diagnosed by prenatal ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The signs of tracheal atresia are immediately apparent at birth. The infant is cyanotic with severe respiratory distress, has no audible cry, and cannot be intubated or ventilated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/3,11-13\">",
"     3,11-13",
"    </a>",
"    ]. Males are affected more often than females (2:1), and other congenital anomalies are present in 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tracheal atresia may be part of a pattern of congenital malformations that overlaps with, but is distinct from, the VACTERL association (a constellation of malformations including vertebral, anal, tracheoesophageal, renal, cardiac, and limb defects) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Other reports have described tracheal agenesis in association with a spectrum of congenital anomalies described as TACRD (tracheal",
"    <span class=\"nowrap\">",
"     agenesis/atresia,",
"    </span>",
"    complex congenital cardiac abnormalities, radial ray defects, and duodenal atresia) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/16\">",
"     16",
"    </a>",
"    ]. In a series of approximately 100 cases of tracheal agenesis, other lower respiratory tract anomalies and complex cardiac anomalies occurred frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/15\">",
"     15",
"    </a>",
"    ]. Four groups of associated anomalies were identified, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Group I &ndash; anomalies restricted to the trachea, larynx, and cardiovascular system",
"     </li>",
"     <li>",
"      Group II &ndash; severe cardiac defects and lung lobation anomalies",
"     </li>",
"     <li>",
"      Group III &ndash; caudal and thoracic anomalies, with frequent anal and renal defects",
"     </li>",
"     <li>",
"      Group IV &ndash; high incidence of aberrant vessels, complex cardiac defects, lung lobation abnormalities, and anomalies of other foregut derivatives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal agenesis results from abnormal development of the laryngotracheal groove early in gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. The cause is unknown and is likely heterogeneous. One mechanism that would also account for the associated anomalies involves abnormal epithelial-mesenchymal interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/15\">",
"     15",
"    </a>",
"    ]. Alternatively, disrupted vascular development in a primary developmental field may result in the features typical of Group IV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, tracheal atresia has been considered lethal. However, resuscitation may be possible if a fistula is present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. If the infant can be resuscitated, surgical correction can be attempted, although the prognosis for survival remains guarded at best [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The development of Ex-utero Intrapartum Treatment (EXIT or fetal surgery) has marginally improved the prognosis for infants diagnosed with tracheal atresia on prenatal ultrasound. A number of case reports describe the successful management of infants with tracheal atresia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TRACHEAL STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal stenosis is a rare anomaly that occurs less often than laryngeal or other tracheal malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. The narrowing results from complete or nearly complete rings of cartilage. Three patterns are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Segmental stenosis that can occur anywhere in the tracheobronchial tree (50 percent)",
"     </li>",
"     <li>",
"      Generalized or complete",
"      <span class=\"nowrap\">",
"       stenosis/hypoplasia",
"      </span>",
"      (30 percent)",
"     </li>",
"     <li>",
"      Funnel-shaped lesion often associated with a pulmonary artery sling (20 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tracheal stenosis often is associated with other malformations of the respiratory tract, esophagus, or skeleton [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/28\">",
"     28",
"    </a>",
"    ]. However, in a small series of premature infants with tracheal stenosis, none had accompanying abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age at onset and severity of symptoms depend upon the degree of stenosis. Complete stenosis presents in newborns, whereas segmental or funnel-shaped lesions may become symptomatic later. Infants typically present with severe respiratory distress, cyanosis, and feeding difficulty. Other findings may include inspiratory stridor or a monophonic expiratory wheeze refractory to bronchodilator therapy. Older patients can present with these findings or recurrent pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Life-threatening deterioration may result when inflammation or mucus plugs cause further tracheal narrowing. Endotracheal intubation usually can be performed in these patients, although advancing the endotracheal tube may not be possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs or fluoroscopy occasionally can demonstrate narrowing of the trachea. However, bronchoscopy usually is needed to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/24\">",
"     24",
"    </a>",
"    ]. Computed tomography (CT) or magnetic resonance imaging (MRI) may be useful to define the extent of narrowing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Advances in CT technology with three-dimensional airway reconstruction have led to the development of \"virtual tracheobronchoscopy\", which has enhanced the diagnosis of tracheobronchial anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal stenosis requires surgical correction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/35\">",
"     35",
"    </a>",
"    ], which can be accomplished by balloon dilatation for short stenoses and excision or tracheoplasty for longer stenoses. Balloon dilatation followed by placement of expandable stents has been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/36\">",
"     36",
"    </a>",
"    ]. Refinements in both surgical and non-invasive techniques for the management of tracheal stenosis have resulted in improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/37-46\">",
"     37-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the outcome of isolated short segment stenosis has been relatively good, whereas long segment stenosis has been considered incompatible with survival. However, as mentioned above, advances in surgical management have decreased the mortality rate of severely affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of mortality remains significant when tracheal stenosis is associated with other conditions. In one series, 5 of 16 infants with tracheal stenosis died, although all who died presented with cardiovascular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/49\">",
"     49",
"    </a>",
"    ]. In another report, patients with tracheal stenosis often required prolonged ventilator support (median duration 59 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/50\">",
"     50",
"    </a>",
"    ]. However, the duration of ventilation and extent of narrowing at dynamic contrast bronchography did not predict survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TRACHEOMALACIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheomalacia is a relatively common anomaly of the upper respiratory tract characterized by dynamic collapse of the trachea during breathing, resulting in airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. Because most lesions are intrathoracic, airway collapse typically occurs during expiration. Extrathoracic lesions in the cervical trachea are rare and lead to collapse during inspiration.",
"   </p>",
"   <p>",
"    Tracheobronchomalacia is the more general term for dynamic collapse of large or small airways. Classification of this disorder is based upon clinical, endoscopic, and histopathologic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/56\">",
"     56",
"    </a>",
"    ]. Three types of lesions are described, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 is caused by an intrinsic defect in the cartilaginous portion of the trachea leading to an increased proportion of membranous trachea. The lack of sufficient rigid support results in airway collapse.",
"     </li>",
"     <li>",
"      Type 2 is caused by extrinsic tracheal compression by cardiovascular structures, tumors, lymph nodes, or other masses [",
"      <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/3,57-60\">",
"       3,57-60",
"      </a>",
"      ]. This type can be congenital or acquired.",
"     </li>",
"     <li>",
"      Type 3 lesions result from prolonged positive pressure ventilation or an",
"      <span class=\"nowrap\">",
"       infectious/inflammatory",
"      </span>",
"      process that undermines the intrinsic cartilaginous support of the trachea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tracheomalacia is a frequent complication of surgical repair of esophageal atresia (EA) and tracheoesophageal fistula. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Tracheoesophageal fistula and esophageal atresia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms depend upon the location and severity of the tracheal lesion. Intrathoracic lesions typically present with a recurrent harsh, barking, or croup-like cough, whereas extrathoracic lesions cause inspiratory stridor; both may result in respiratory distress. A greater extent of collapse is associated with earlier presentation. Infants and young children with tracheobronchomalacia tend to have more frequent respiratory illnesses and delayed recovery from these illnesses as compared to control patients, but the site and severity of the malacia does not predict the respiratory illness profile [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs in affected patients often are normal. In a study of 144 patients evaluated using airway radiographs, microlaryngoscopy (examination of the supraglottic structures with a small endoscope), and bronchoscopy, sensitivity of the radiograph to detect tracheomalacia was only 62 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/62\">",
"     62",
"    </a>",
"    ]. Changes in airway caliber during fluoroscopy occasionally can establish a diagnosis.",
"   </p>",
"   <p>",
"    Definitive diagnosis usually is made by bronchoscopy during spontaneous breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/24\">",
"     24",
"    </a>",
"    ]. With this technique, the trachea is observed to collapse during expiration. Noninvasive diagnosis of this disorder may be improved by newer imaging techniques, including multidetector CT in which end-expiratory and end-inspiratory images are obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Children older than age five are usually able to voluntarily perform the breathing maneuvers that are necessary for this technique; younger children and infants usually require endotracheal intubation. A combined approach using endoscopy and three-dimensional CT scan also has been advocated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard computed tomography (CT) or magnetic resonance imaging (MRI) are not well suited for primary diagnosis of tracheobronchomalacia because images are generally obtained at end inspiration and malacia may not be evident. However, in some cases these imaging studies may be helpful in defining the extent of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Angio-MRI can be used to diagnose vascular anomalies which can cause extrinsic tracheobronchial compression and are sometimes associated with tracheomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis of this disorder is good in children with no associated problems. Most affected infants improve spontaneously by 6 to 12 months of age as airway caliber increases and cartilage develops. However, some remain symptomatic or have exercise intolerance as adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intervention may be needed in children with life-threatening episodes of airway obstruction, recurrent infection, respiratory failure, or failure to thrive. Although severely affected patients with type 1 or 3 tracheomalacia may require positive pressure ventilatory support, tracheal surgery, placement of a tracheal stent, or suspension of the trachea (tracheopexy) may be other options [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/68-73\">",
"     68-73",
"    </a>",
"    ]. Some literature suggests potential roles for airway stents in children, though the use of airway stents typically is reserved for patients whose prognosis is otherwise grim [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/50,74,75\">",
"     50,74,75",
"    </a>",
"    ]. The relatively low use of these devices is secondary to the frequency of problems related to their use. Expanding metallic stents, in particular, have been associated with a high incidence of complications and are used only in life-threatening situations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Aortopexy (suspension of the aorta) is performed when tracheomalacia is caused by extrinsic vascular compression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/68,78-80\">",
"     68,78-80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INTRINSIC TRACHEAL OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrinsic obstruction of the tracheal lumen usually is caused by hemangiomas, hamartomas, or webs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/3,60,81\">",
"     3,60,81",
"    </a>",
"    ]. Affected patients present with stridor or fixed, monophonic \"wheezing\" (a noise similar to that heard in asthma, but caused by tracheal narrowing rather than increased lower airways resistance) and respiratory distress that ranges from mild to severe, depending upon the extent of tracheal narrowing. The stridor can be inspiratory, expiratory, or both.",
"   </p>",
"   <p>",
"    Bronchoscopy is required to establish the diagnosis, although high resolution imaging studies may identify large lesions. Therapy consists of surgical resection of the obstructing lesion. The long-term prognosis usually is good.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TRACHEOESOPHAGEAL FISTULA AND ESOPHAGEAL ATRESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheoesophageal fistula (TEF) is a common congenital anomaly of the respiratory tract, with an incidence of approximately 1 in 3500 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. TEF typically occurs with esophageal atresia (EA). EA and TEF are classified according to their anatomic configuration (",
"    <a class=\"graphic graphic_figure graphicRef52914 \" href=\"UTD.htm?40/26/41382\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/85\">",
"     85",
"    </a>",
"    ]. Type C, which consists of a proximal esophageal pouch and a distal TEF, accounts for 84 percent of cases. TEF occurs without EA (H-type fistula) in only 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Other rare variations also have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TEF and EA are caused by a defect in the lateral septation of the foregut into the esophagus and trachea. The fistula tract is thought to derive from a branch of the embryonic lung bud that fails to undergo branching because of defective epithelial-mesenchymal interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. There are associated anomalies in about half of the cases of TEF and EA, often as part of the VACTERL association [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19161?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to congenital malformations\", section on 'Association'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of TEF depends upon the presence or absence of EA. In cases with EA (95 percent), polyhydramnios occurs in approximately two-thirds of pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/93\">",
"     93",
"    </a>",
"    ]. However, many cases are not detected prenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/94\">",
"     94",
"    </a>",
"    ]. Additional clinical features relate to the presence of the VACTERL association [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with EA become symptomatic immediately after birth with excessive secretions that cause drooling, choking, respiratory distress, and the inability to feed. A fistula between the trachea and distal esophagus leads to gastric distension. Reflux of gastric contents through the TEF results in aspiration pneumonia and contributes to morbidity.",
"   </p>",
"   <p>",
"    Patients with H-Type TEFs may present early if the defect is large, with coughing and choking associated with feeding as the milk is aspirated through the fistula. However, smaller defects of this type may not be symptomatic in the newborn period. In one series, the delay in diagnosis ranged from 26 days to 4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/95\">",
"     95",
"    </a>",
"    ]. These patients typically have a prolonged history of mild respiratory distress associated with feeding or recurrent episodes of pneumonia. On occasion, the diagnosis may be delayed for longer periods and even into adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of EA can be made by attempting to pass a catheter into the stomach. In affected infants, the catheter cannot be passed further than approximately 10 to 15 cm. This finding can be confirmed with an anterior-posterior chest radiograph that demonstrates the catheter curled in the upper esophageal pouch. A distal TEF often can be seen on a lateral chest radiograph; both views will reveal a gas-filled gastrointestinal tract. When the diagnosis is uncertain or a proximal TEF is suspected, a small amount of water-soluble contrast material placed in the esophageal pouch under fluoroscopic guidance will confirm the presence of EA. The contrast material must be removed immediately to avoid regurgitation and aspiration.",
"   </p>",
"   <p>",
"    Diagnosis of isolated TEF is more challenging. Demonstration of the fistula should be attempted with an upper gastrointestinal series using thickened water-soluble contrast material. The traditional method requires a pull-back technique in which the distal esophagus is filled first and then the catheter is pulled in a cephalad direction. Subsequent studies have suggested equal or better diagnostic sensitivity with contrast swallow radiography [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/97\">",
"     97",
"    </a>",
"    ]. However, the fistulous tract may be missed in these studies. In that case, esophageal endoscopy and bronchoscopy should be used to detect the TEF. Demonstration of the fistula may be accomplished by the appearance in the esophagus of a small amount of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/61/20438?source=see_link\">",
"     methylene blue",
"    </a>",
"    that is injected into the trachea. The use of three-dimensional CT scanning also has been advocated as an additional method for the diagnosis of TEF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/98-100\">",
"     98-100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment consists of surgical ligation of the fistula. With isolated TEF, a cervical approach can be used in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/87,101\">",
"     87,101",
"    </a>",
"    ]. In cases with EA, primary anastomosis of the esophageal segments is preferred. Advances in the medical management of these infants combined with newer surgical techniques have improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/102-110\">",
"     102-110",
"    </a>",
"    ]. Primary repair may not be possible if the distance between esophageal segments is large [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/111\">",
"     111",
"    </a>",
"    ]. In that case, staged procedures have been performed that include elongation of the esophagus, interposition of the colon, and gastric transposition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In very low birth weight infants, this staged approach has been associated with improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for isolated TEF is generally good [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/115\">",
"     115",
"    </a>",
"    ]. Outcome of infants with EA and TEF is more guarded and depends upon associated abnormalities. In one report, 87 percent of patients with EA or EA and TEF (1980 through 1997) survived; 61 percent of early deaths were associated with cardiac and chromosomal anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/116\">",
"     116",
"    </a>",
"    ]. Mortality rates for EA and TEF were greater for infants with associated cardiac disease (42 versus 12 percent without). Low birth weight was not a significant risk factor. One review reports significantly higher survival rates for infants with and without associated congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/117\">",
"     117",
"    </a>",
"    ]. In this series, birth weight was a factor in survival. The gap length of the esophageal atresia (the distance between the two esophageal pouches) also may determine the prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications after EA and TEF repair in a series of 227 cases included anastomotic leak (16 percent), esophageal stricture (35 percent), and recurrent fistulae (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/119\">",
"     119",
"    </a>",
"    ]; esophageal stricture has been successfully managed with endoscopic balloon dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. Tracheomalacia occurred in 15 percent of cases; 40 percent of these required surgical repair. Disturbed peristalsis and delayed gastric emptying are common and contribute to gastroesophageal reflux and aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/122\">",
"     122",
"    </a>",
"    ]. However, early routine upper gastrointestinal series in the absence of clinical findings did not predict the development of postoperative problems [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/123\">",
"     123",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Tracheomalacia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Motility disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/124,125\">",
"     124,125",
"    </a>",
"    ] and respiratory function abnormalities persist on long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/126-129\">",
"     126-129",
"    </a>",
"    ]. In a case series of adults with esophageal atresia repaired during infancy, 58 percent had reflux esophagitis; 11 percent had Barrett's esophagus and 42 percent had strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/130\">",
"     130",
"    </a>",
"    ]. Other reviews have cited similar long-term complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/131-134\">",
"     131-134",
"    </a>",
"    ]. One series reports a substantially increased risk of esophageal squamous cell cancer developing after 40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/135\">",
"     135",
"    </a>",
"    ]. Esophageal cancer developed in 4 of 309 patients in the series, approximately 50 times the rate in the general population. These findings suggest a role for endoscopic surveillance of these patients during adulthood. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TRACHEAL BRONCHUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal bronchus refers to an abnormal bronchus that originates from the trachea, carina, or other bronchus and is directed to the upper lobes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/136\">",
"     136",
"    </a>",
"    ]. In a series of 35 cases, most cases originated from the bronchus (69 percent) rather than the trachea (23 percent) or carina (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/137\">",
"     137",
"    </a>",
"    ]. In another large series, tracheal bronchus accounted for 7.5 percent of tracheobronchial anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/138\">",
"     138",
"    </a>",
"    ]. Most cases involve the right upper lobe. A specific malformation in which a single right upper lobe bronchus arises from the right side of the trachea above the carina is known as bronchus suis (or \"pig bronchus\") because it is the normal anatomic configuration seen in pigs and other ruminant animals.",
"   </p>",
"   <p>",
"    Tracheal bronchus is a common airway malformation, with an incidence of 0.1 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/139,140\">",
"     139,140",
"    </a>",
"    ]. The defect in embryogenesis that results in this disorder is uncertain. Possible mechanisms include abnormalities in migration, selection, or reduction of airways during development [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal bronchus usually is asymptomatic and considered an incidental finding on bronchoscopy performed for unrelated reasons. However, affected children can have respiratory morbidity. In one series, 18 patients ranging from 1 day to 54 months of age presented with recurrent pneumonia (50 percent), stridor (33 percent), respiratory distress (11 percent), or thoracic mass (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/141\">",
"     141",
"    </a>",
"    ]. Most of them had other congenital anomalies. Other presentations include prolonged right upper lobe atelectasis complicating endotracheal intubation and mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/142\">",
"     142",
"    </a>",
"    ] and lobar emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/143\">",
"     143",
"    </a>",
"    ]. There is a report of an adult presenting with bilateral tracheal bronchi and hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/144\">",
"     144",
"    </a>",
"    ]. The diagnosis is made at bronchoscopy or by CT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/137,145-147\">",
"     137,145-147",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30487?source=see_link\">",
"     \"Radiographic appearance of developmental anomalies of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific therapy is indicated if the patient is asymptomatic. Recurrent pneumonia and localized bronchiectasis are managed with antibiotics and pulmonary toilet, including postural drainage and chest physiotherapy. Patients who do not respond to medical management may require lobectomy. The prognosis for patients with this anomaly typically is excellent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     LOWER AIRWAY ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental anomalies of the bronchi and lower airways (atresia, stenosis, or malacia) and abnormalities resulting in intrinsic obstruction or extrinsic compression are similar to those that occur in the trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/26,34\">",
"     26,34",
"    </a>",
"    ]. They also can be associated with congenital malformations such as bronchogenic cysts. The radiographic appearance of these malformations and other developmental anomalies of the lung is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30487?source=see_link\">",
"     \"Radiographic appearance of developmental anomalies of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bronchial atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial atresia typically is identified as an incidental finding on a chest radiograph obtained in an asymptomatic older child or adult [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/148\">",
"     148",
"    </a>",
"    ]. Because no communication with the normal tracheobronchial tree exists, infection is unusual.",
"   </p>",
"   <p>",
"    This condition appears on chest radiograph as a hyperinflated or hyperlucent area that may compress adjacent tissue and cause a shift of the mediastinum. The hyperinflation is thought to result from unidirectional flow through collateral airways (pores of Kohn, canals of Lambert). A left-sided predominance occurs for unknown reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/3\">",
"     3",
"    </a>",
"    ]. When the appearance is atypical, diagnosis can be confirmed by computed tomography (CT).",
"   </p>",
"   <p>",
"    Some authors have suggested that bronchial atresia may represent a common pathogenic pathway for a variety of congenital lung malformations including intralobar sequestration, congenital cystic adenomatoid malformation, and congenial lobar emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/149\">",
"     149",
"    </a>",
"    ]. This theory is plausible based on common histopathologic findings among these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/150,151\">",
"     150,151",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Bronchial stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial stenosis refers to narrowing of the bronchi at any point in the bronchial tree. This condition can be focal or diffuse. Affected patients present in infancy with wheezing refractory to bronchodilators and recurrent pneumonia. The chest radiograph typically shows hyperinflation and air trapping.",
"   </p>",
"   <p>",
"    Bronchoscopy can confirm the diagnosis in lesions that are proximal. Detection of distal lesions is limited by the size of the patient and the bronchoscope. Airway imaging with CT or magnetic resonance imaging (MRI) reconstruction may detect lesions that are more peripheral, although these techniques can miss smaller lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/24,31,32\">",
"     24,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management is supportive. This approach includes antibiotics to treat infection and chest physiotherapy to mobilize secretions, although supporting evidence for the latter is unavailable. Most cases need no intervention, and symptoms usually resolve as the airways grow. However, surgical resection sometimes is indicated in children with serious or recurrent infections who fail medical management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Bronchomalacia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchomalacia refers to dynamic narrowing of the bronchi. It is a relatively common abnormality of the lower airway and often is associated with tracheomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/152\">",
"     152",
"    </a>",
"    ]. Causes include congenital absence of cartilage, extrinsic airway compression, and acquired intrinsic narrowing after infection or lung or heart-lung transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/56,57,153\">",
"     56,57,153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation of this disorder is similar to tracheomalacia and bronchial stenosis. Affected patients present between 1 and 12 months and rarely before 1 month of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/154\">",
"     154",
"    </a>",
"    ]. Typical features include recurrent infections and respiratory distress in severe cases. A fixed expiratory \"wheeze\" (a noise similar to that heard in asthma, but caused by bronchial narrowing rather than increased lower airways resistance), is heard on auscultation.",
"   </p>",
"   <p>",
"    The diagnosis is made with bronchoscopy or CT imaging with airway reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/153,155-157\">",
"     153,155-157",
"    </a>",
"    ]. Management is similar to that for tracheomalacia. Most patients require no intervention, although unusual cases need continuous positive airway pressure to prevent lobar collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/154\">",
"     154",
"    </a>",
"    ]. Patients with severe respiratory distress may require surgical repair of anomalous vessels, suspension of the involved airway (bronchopexy), airway stents, or lobectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/57,158,159\">",
"     57,158,159",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Bronchial obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous disorders can cause extrinsic or intrinsic obstruction of the lower airways. Extrinsic obstruction or compression usually results from aberrant blood vessels, although it may be caused by congenital cystic malformations such as bronchogenic cyst. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Bronchogenic cyst'",
"    </a>",
"    below.) Intrinsic obstruction can be caused by acquired lesions such as bronchial webs, hamartomas, plasmacytomas, and other tumors.",
"   </p>",
"   <p>",
"    These conditions are rare and typically present with recurrent infection distal to the obstruction. The diagnosis is made by endoscopy or high-resolution imaging studies. Surgery is performed to exclude malignancy and prevent the recurrence of symptoms. It usually is curative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bronchogenic cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchogenic cysts arise from anomalous budding of the foregut during development and represent part of the spectrum of bronchopulmonary foregut malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/26,160,161\">",
"     26,160,161",
"    </a>",
"    ]. They can occur at any point throughout the tracheobronchial tree. Cervical, intrapleural, cutaneous, esophageal, cardiac, and subdiaphragmatic retroperitoneal bronchogenic cysts are unusual occurrences but have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/162-173\">",
"     162-173",
"    </a>",
"    ]. These lesions, although rare, are among the most common lower respiratory tract malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/174-178\">",
"     174-178",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients typically present during the second decade of life with recurrent coughing, wheezing (which may simulate asthma), and pneumonia, but they may become symptomatic in infancy or adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/178-181\">",
"     178-181",
"    </a>",
"    ]. Newborns with rapidly enlarging central cysts can develop respiratory distress, cyanosis, and feeding difficulty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/182-185\">",
"     182-185",
"    </a>",
"    ]. Bronchogenic cysts also may be detected as incidental findings on chest radiographs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchogenic cysts appear on chest radiograph as round water-density masses that may have air-fluid levels associated with previous or current infection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75842 \" href=\"UTD.htm?15/5/15441\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/186,187\">",
"     186,187",
"    </a>",
"    ]. CT typically shows sharply marginated cystic mediastinal masses of soft tissue or water attenuation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69181 \" href=\"UTD.htm?34/6/34912\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/187\">",
"     187",
"    </a>",
"    ]. Lesions that appear solid on CT usually can be characterized as cystic by MRI. The radiographic appearance of bronchogenic cysts and other developmental anomalies of the lung is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30487?source=see_link\">",
"     \"Radiographic appearance of developmental anomalies of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gross pathologic examination demonstrates unilocular cysts that are filled with thick, clear fluid and do not communicate with the tracheobronchial tree (",
"    <a class=\"graphic graphic_picture graphicRef54933 \" href=\"UTD.htm?18/8/18563\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/187\">",
"     187",
"    </a>",
"    ]. On histologic examination, the cyst is lined by respiratory epithelium with occasional foci of squamous metaplasia; the wall resembles that of larger airways and contains smooth muscle, glands, and cartilage (",
"    <a class=\"graphic graphic_picture graphicRef52817 \" href=\"UTD.htm?31/39/32373\">",
"     picture 2",
"    </a>",
"    ). The presence of cartilage plates is the most reliable diagnostic criterion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of a bronchogenic cyst consists of surgical excision by partial or total lobectomy. This procedure is curative. Controversy exists regarding the need for resection when patients are asymptomatic. We recommend surgery in all cases because of the likelihood of eventual development of symptoms and the potential for serious illness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/179\">",
"     179",
"    </a>",
"    ]. In addition, malignant degeneration may occur with this disorder, as in other congenital cystic anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/188\">",
"     188",
"    </a>",
"    ]. Although surgical excision is typically straightforward, operative complications have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/189-191\">",
"     189-191",
"    </a>",
"    ]. The prenatal ultrasound identification of large cysts compressing cardiovascular structures warrants in utero thoracentesis to prevent fetal hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?28/27/29114/abstract/182\">",
"     182",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tracheal atresia is a rare disorder that is usually lethal. It may be identified on prenatal ultrasound, or present at birth with cyanosis, severe respiratory distress, and no audible cry. The anatomy prevents intubation or ventilation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tracheal atresia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tracheal stenosis is a rare anomaly characterized by segmental, funnel-shaped, or generalized stenosis, caused by rings of cartilage. The presentation varies markedly depending on the degree and type of stenosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tracheal stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tracheomalacia is a relatively common anomaly of the upper respiratory tract characterized by dynamic collapse of the trachea during breathing. Intrathoracic lesions are most common, and tend to cause symptoms during expiration (eg, a croup-like cough), whereas extrathoracic lesions cause inspiratory stridor. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Tracheomalacia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tracheoesophageal fistula (TEF) is a common congenital anomaly of the respiratory tract, and typically occurs with esophageal atresia (EA) (",
"      <a class=\"graphic graphic_figure graphicRef52914 \" href=\"UTD.htm?40/26/41382\">",
"       figure 1",
"      </a>",
"      ). Infants with EA often have a history of polyhydramnios and present with excessive oral secretions and inability to feed. Those with a fistula between the trachea and the distal esophagus may have abdominal distension and aspiration pneumonia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Tracheoesophageal fistula and esophageal atresia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchial stenosis refers to narrowing of the bronchi at any point in the bronchial tree. This condition can be focal or diffuse. Affected patients present in infancy with wheezing refractory to bronchodilators and recurrent pneumonia. The chest radiograph typically shows hyperinflation and air trapping. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Bronchial stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchomalacia is the dynamic narrowing of the bronchi, and may be caused by congenital absence of cartilage, extrinsic airway compression, and acquired intrinsic narrowing after infection. Symptoms include a fixed expiratory wheeze in an infant, and sometimes recurrent infections and respiratory distress. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Bronchomalacia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchogenic cysts are unilocular fluid-filled lesions, usually in the lungs or mediastinum; they do not communicate with the tracheobronchial tree. Affected patients typically present during the second decade of life with recurrent coughing, wheezing (which may simulate asthma), and pneumonia. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Bronchogenic cyst'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/1\">",
"      De Jos&eacute; Mar&iacute;a B, Drudis R, Moncl&uacute;s E, et al. Management of tracheal agenesis. Paediatr Anaesth 2000; 10:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/2\">",
"      Felix JF, van Looij MA, Pruijsten RV, et al. Agenesis of the trachea: phenotypic expression of a rare cause of fatal neonatal respiratory insufficiency in six patients. Int J Pediatr Otorhinolaryngol 2006; 70:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/3\">",
"      Landing BH, Dixon LG. Congenital malformations and genetic disorders of the respiratory tract (larynx, trachea, bronchi, and lungs). Am Rev Respir Dis 1979; 120:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/4\">",
"      Kerschner J, Klotch DW. Tracheal agenesis: a case report and review of the literature. Otolaryngol Head Neck Surg 1997; 116:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/5\">",
"      Fraser N, Stewart RJ, Grant J, et al. Tracheal agenesis with unique anatomy. J Pediatr Surg 2005; 40:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/6\">",
"      Pratap A, Saha GS, Bhattarai BK, et al. Tracheal agenesis type B: further evidence to a lethal congenital tracheal malformation. J Pediatr Surg 2007; 42:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/7\">",
"      Haben CM, Rappaport JM, Clarke KD. Tracheal agenesis. J Am Coll Surg 2002; 194:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/8\">",
"      FLOYD J, CAMPBELL DC Jr, DOMINY DE. Agenesis of the trachea. Am Rev Respir Dis 1962; 86:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/9\">",
"      Witters I, Fryns JP, De Catte L, Moerman P. Prenatal diagnosis and pulmonary pathology in congenital high airway obstruction sequence. Prenat Diagn 2009; 29:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/10\">",
"      Mong A, Johnson AM, Kramer SS, et al. Congenital high airway obstruction syndrome: MR/US findings, effect on management, and outcome. Pediatr Radiol 2008; 38:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/11\">",
"      Wiatrak BJ. Congenital anomalies of the larynx and trachea. Otolaryngol Clin North Am 2000; 33:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/12\">",
"      van Veenendaal MB, Liem KD, Marres HA. Congenital absence of the trachea. Eur J Pediatr 2000; 159:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/13\">",
"      Heimann K, Bartz C, Naami A, et al. Three new cases of congenital agenesis of the trachea. Eur J Pediatr 2007; 166:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/14\">",
"      Evans JA, Reggin J, Greenberg C. Tracheal agenesis and associated malformations: a comparison with tracheoesophageal fistula and the VACTERL association. Am J Med Genet 1985; 21:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/15\">",
"      Evans JA, Greenberg CR, Erdile L. Tracheal agenesis revisited: analysis of associated anomalies. Am J Med Genet 1999; 82:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/16\">",
"      Wei JL, Rodeberg D, Thompson DM. Tracheal agenesis with anomalies found in both VACTERL and TACRD associations. Int J Pediatr Otorhinolaryngol 2003; 67:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/17\">",
"      Hill SA, Milam M, Manaligod JM. Tracheal agenesis: diagnosis and management. Int J Pediatr Otorhinolaryngol 2001; 59:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/18\">",
"      Baroncini-Cornea S, Fae M, Gargiulo G, et al. Tracheal agenesis: management of the first 10 months of life. Paediatr Anaesth 2004; 14:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/19\">",
"      Lander TA, Schauer G, Bendel-Stenzel E, Sidman JD. Tracheal agenesis in newborns. Laryngoscope 2004; 114:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/20\">",
"      Hartnick CJ, Rutter M, Lang F, et al. Congenital high airway obstruction syndrome and airway reconstruction: an evolving paradigm. Arch Otolaryngol Head Neck Surg 2002; 128:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/21\">",
"      Rahbar R, Vogel A, Myers LB, et al. Fetal surgery in otolaryngology: a new era in the diagnosis and management of fetal airway obstruction because of advances in prenatal imaging. Arch Otolaryngol Head Neck Surg 2005; 131:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/22\">",
"      Kanamori Y, Kitano Y, Hashizume K, et al. A case of laryngeal atresia (congenital high airway obstruction syndrome) with chromosome 5p deletion syndrome rescued by ex utero intrapartum treatment. J Pediatr Surg 2004; 39:E25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/23\">",
"      Okuyama H, Kubota A, Kawahara H, et al. Congenital laryngeal atresia associated with esophageal atresia and tracheoesophageal fistula: a case of long-term survival. J Pediatr Surg 2006; 41:e29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/24\">",
"      Altman KW, Wetmore RF, Mahboubi S. Comparison of endoscopy and radiographic fluoroscopy in the evaluation of pediatric congenital airway abnormalities. Int J Pediatr Otorhinolaryngol 1998; 44:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/25\">",
"      Altman KW, Wetmore RF, Marsh RR. Congenital airway abnormalities in patients requiring hospitalization. Arch Otolaryngol Head Neck Surg 1999; 125:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/26\">",
"      Berrocal T, Madrid C, Novo S, et al. Congenital anomalies of the tracheobronchial tree, lung, and mediastinum: embryology, radiology, and pathology. Radiographics 2004; 24:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/27\">",
"      Airway Reconstruction Team. Recent challenges in the management of congenital tracheal stenosis: an individualized approach. J Pediatr Surg 2005; 40:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/28\">",
"      Benjamin B, Pitkin J, Cohen D. Congenital tracheal stenosis. Ann Otol Rhinol Laryngol 1981; 90:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/29\">",
"      Hauft SM, Perlman JM, Siegel MJ, Muntz HR. Tracheal stenosis in the sick premature infant. Clinical and radiologic features. Am J Dis Child 1988; 142:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/30\">",
"      S&aacute;nchez I, Navarro H, M&eacute;ndez M, et al. Clinical characteristics of children with tracheobronchial anomalies. Pediatr Pulmonol 2003; 35:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/31\">",
"      Remy J, Remy-Jardin M, Artaud D, Fribourg M. Multiplanar and three-dimensional reconstruction techniques in CT: impact on chest diseases. Eur Radiol 1998; 8:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/32\">",
"      Rimell FL, Shapiro AM, Meza MP, et al. Magnetic resonance imaging of the pediatric airway. Arch Otolaryngol Head Neck Surg 1997; 123:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/33\">",
"      Heyer CM, Nuesslein TG, Jung D, et al. Tracheobronchial anomalies and stenoses: detection with low-dose multidetector CT with virtual tracheobronchoscopy--comparison with flexible tracheobronchoscopy. Radiology 2007; 242:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/34\">",
"      Desir A, Ghaye B. Congenital abnormalities of intrathoracic airways. Radiol Clin North Am 2009; 47:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/35\">",
"      Rimell FL, Stool SE. Diagnosis and management of pediatric tracheal stenosis. Otolaryngol Clin North Am 1995; 28:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/36\">",
"      Maeda K, Yasufuku M, Yamamoto T. A new approach to the treatment of congenital tracheal stenosis: Balloon tracheoplasty and expandable metallic stenting. J Pediatr Surg 2001; 36:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/37\">",
"      McLaren CA, Elliott MJ, Roebuck DJ. Tracheobronchial intervention in children. Eur J Radiol 2005; 53:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/38\">",
"      Kim HJ, Shin JH, Hong SJ, et al. Treatment of congenital tracheal stenosis with balloon-assisted posterior tracheal splitting and temporary placement of a covered retrievable metallic stent. J Vasc Interv Radiol 2005; 16:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/39\">",
"      Elliott M, Roebuck D, Noctor C, et al. The management of congenital tracheal stenosis. Int J Pediatr Otorhinolaryngol 2003; 67 Suppl 1:S183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/40\">",
"      Tsugawa C, Nishijima E, Muraji T, et al. Tracheoplasty for long segment congenital tracheal stenosis: analysis of 29 patients over two decades. J Pediatr Surg 2003; 38:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/41\">",
"      Kocyildirim E, Kanani M, Roebuck D, et al. Long-segment tracheal stenosis: slide tracheoplasty and a multidisciplinary approach improve outcomes and reduce costs. J Thorac Cardiovasc Surg 2004; 128:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/42\">",
"      Ant&oacute;n-Pacheco JL, Cano I, Garc&iacute;a A, et al. Patterns of management of congenital tracheal stenosis. J Pediatr Surg 2003; 38:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/43\">",
"      Ant&oacute;n-Pacheco JL, Cano I, Comas J, et al. Management of congenital tracheal stenosis in infancy. Eur J Cardiothorac Surg 2006; 29:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/44\">",
"      Wyatt ME, Hartley BE. Laryngotracheal reconstruction in congenital laryngeal webs and atresias. Otolaryngol Head Neck Surg 2005; 132:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/45\">",
"      Hasaniya N, elZein CF, Mara S, et al. Alternative approach to the surgical management of congenital tracheal stenosis. Ann Thorac Surg 2006; 82:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/46\">",
"      Okamoto T, Nishijima E, Maruo A, et al. Congenital tracheal stenosis: the prognostic significance of associated cardiovascular anomalies and the optimal timing of surgical treatment. J Pediatr Surg 2009; 44:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/47\">",
"      Faust RA, Stroh B, Rimell F. The near complete tracheal ring deformity. Int J Pediatr Otorhinolaryngol 1998; 45:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/48\">",
"      Chiu PP, Rusan M, Williams WG, et al. Long-term outcomes of clinically significant vascular rings associated with congenital tracheal stenosis. J Pediatr Surg 2006; 41:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/49\">",
"      Burden RJ, Shann F, Butt W, Ditchfield M. Tracheobronchial malacia and stenosis in children in intensive care: bronchograms help to predict oucome. Thorax 1999; 54:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/50\">",
"      Inwald DP, Roebuck D, Elliott MJ, Mok Q. Current management and outcome of tracheobronchial malacia and stenosis presenting to the paediatric intensive care unit. Intensive Care Med 2001; 27:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/51\">",
"      Carden KA, Boiselle PM, Waltz DA, Ernst A. Tracheomalacia and tracheobronchomalacia in children and adults: an in-depth review. Chest 2005; 127:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/52\">",
"      Austin J, Ali T. Tracheomalacia and bronchomalacia in children: pathophysiology, assessment, treatment and anaesthesia management. Paediatr Anaesth 2003; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/53\">",
"      McNamara VM, Crabbe DC. Tracheomalacia. Paediatr Respir Rev 2004; 5:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/54\">",
"      Wright CD. Tracheomalacia. Chest Surg Clin N Am 2003; 13:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/55\">",
"      Pillai JB, Smith J, Hasan A, Spencer D. Review of pediatric airway malacia and its management, with emphasis on stenting. Eur J Cardiothorac Surg 2005; 27:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/56\">",
"      Mair EA, Parsons DS. Pediatric tracheobronchomalacia and major airway collapse. Ann Otol Rhinol Laryngol 1992; 101:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/57\">",
"      Sebening C, Jakob H, Tochtermann U, et al. Vascular tracheobronchial compression syndromes-- experience in surgical treatment and literature review. Thorac Cardiovasc Surg 2000; 48:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/58\">",
"      McLaughlin RB Jr, Wetmore RF, Tavill MA, et al. Vascular anomalies causing symptomatic tracheobronchial compression. Laryngoscope 1999; 109:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/59\">",
"      Kazim R, Berdon WE, Montoya CH, et al. Tracheobronchial anomalies in children with congenital cardiac disease. J Cardiothorac Vasc Anesth 1998; 12:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/60\">",
"      McCarthy MJ, Rosado-de-Christenson ML. Tumors of the trachea. J Thorac Imaging 1995; 10:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/61\">",
"      Masters IB, Zimmerman PV, Pandeya N, et al. Quantified tracheobronchomalacia disorders and their clinical profiles in children. Chest 2008; 133:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/62\">",
"      Walner DL, Ouanounou S, Donnelly LF, Cotton RT. Utility of radiographs in the evaluation of pediatric upper airway obstruction. Ann Otol Rhinol Laryngol 1999; 108:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/63\">",
"      Lee EY, Boiselle PM. Tracheobronchomalacia in infants and children: multidetector CT evaluation. Radiology 2009; 252:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/64\">",
"      Hein E, Rogalla P, Hentschel C, et al. Dynamic and quantitative assessment of tracheomalacia by electron beam tomography: correlation with clinical symptoms and bronchoscopy. J Comput Assist Tomogr 2000; 24:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/65\">",
"      Briganti V, Oriolo L, Mangia G, et al. Tracheomalacia in esophageal atresia. Usefulness of preoperative imaging evaluation for tailored surgical correction. J Pediatr Surg 2006; 41:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/66\">",
"      Briganti V, Oriolo L, Buffa V, et al. Tracheomalacia in oesophageal atresia: morphological considerations by endoscopic and CT study. Eur J Cardiothorac Surg 2005; 28:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/67\">",
"      Malik TH, Bruce IA, Kaushik V, et al. The role of magnetic resonance imaging in the assessment of suspected extrinsic tracheobronchial compression due to vascular anomalies. Arch Dis Child 2006; 91:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/68\">",
"      Morabito A, MacKinnon E, Alizai N, et al. The anterior mediastinal approach for management of tracheomalacia. J Pediatr Surg 2000; 35:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/69\">",
"      Casiano RR, Numa WA, Nurko YJ. Efficacy of transoral intraluminal Wallstents for tracheal stenosis or tracheomalacia. Laryngoscope 2000; 110:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/70\">",
"      Furman RH, Backer CL, Dunham ME, et al. The use of balloon-expandable metallic stents in the treatment of pediatric tracheomalacia and bronchomalacia. Arch Otolaryngol Head Neck Surg 1999; 125:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/71\">",
"      Tsugawa C, Nishijima E, Muraji T, et al. A shape memory airway stent for tracheobronchomalacia in children: an experimental and clinical study. J Pediatr Surg 1997; 32:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/72\">",
"      Wright CD. Pediatric tracheal surgery. Chest Surg Clin N Am 2003; 13:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/73\">",
"      Jaquiss RD. Management of pediatric tracheal stenosis and tracheomalacia. Semin Thorac Cardiovasc Surg 2004; 16:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/74\">",
"      Jacobs JP, Quintessenza JA, Botero LM, et al. The role of airway stents in the management of pediatric tracheal, carinal, and bronchial disease. Eur J Cardiothorac Surg 2000; 18:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/75\">",
"      Kumar P, Bush AP, Ladas GP, Goldstraw P. Tracheobronchial obstruction in children: experience with endoscopic airway stenting. Ann Thorac Surg 2003; 75:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/76\">",
"      Vinograd I, Keidar S, Weinberg M, Silbiger A. Treatment of airway obstruction by metallic stents in infants and children. J Thorac Cardiovasc Surg 2005; 130:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/77\">",
"      Nicolai T, Huber RM, Reiter K, et al. Metal airway stent implantation in children: follow-up of seven children. Pediatr Pulmonol 2001; 31:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/78\">",
"      Kamata S, Usui N, Sawai T, et al. Pexis of the great vessels for patients with tracheobronchomalacia in infancy. J Pediatr Surg 2000; 35:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/79\">",
"      Dave S, Currie BG. The role of aortopexy in severe tracheomalacia. J Pediatr Surg 2006; 41:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/80\">",
"      Durkin ET, Krawiec ME, Shaaban AF. Thoracoscopic aortopexy for primary tracheomalacia in a 12-year-old. J Pediatr Surg 2007; 42:E15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/81\">",
"      Phipps CD, Gibson WS, Wood WE. Infantile subglottic hemangioma: a review and presentation of two cases of surgical excision. Int J Pediatr Otorhinolaryngol 1997; 41:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/82\">",
"      Depaepe A, Dolk H, Lechat MF. The epidemiology of tracheo-oesophageal fistula and oesophageal atresia in Europe. EUROCAT Working Group. Arch Dis Child 1993; 68:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/83\">",
"      Robb A, Lander A. Oesophageal atresia and tracheo-oesophageal fistula (Available at: linkinghub.elsevier.com/retrieve/pii/S0263931907001135 [Accessed on November 16, 2007]). Surgery (Oxford) 2007; 25:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/84\">",
"      Keckler SJ, St Peter SD, Valusek PA, et al. VACTERL anomalies in patients with esophageal atresia: an updated delineation of the spectrum and review of the literature. Pediatr Surg Int 2007; 23:309.",
"     </a>",
"    </li>",
"    <li>",
"     Clements BS. Congenital malformations of the lung and airways. In: Pediatric Respiratory Medicine, 1st ed, Taussig LM, Landau LI (Eds), Mosby, St. Louis 1999. Vol 1, p.1115.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/86\">",
"      Clark DC. Esophageal atresia and tracheoesophageal fistula. Am Fam Physician 1999; 59:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/87\">",
"      LaSalle AJ, Andrassy RJ, Ver Steeg K, Ratner I. Congenital tracheoesophageal fistula without esophageal atresia. J Thorac Cardiovasc Surg 1979; 78:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/88\">",
"      Kane TD, Atri P, Potoka DA. Triple fistula: management of a double tracheoesophageal fistula with a third H-type proximal fistula. J Pediatr Surg 2007; 42:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/89\">",
"      Katsura S, Shono T, Yamanouchi T, et al. Esophageal atresia with double tracheoesophageal fistula--a case report and review of the literature. Eur J Pediatr Surg 2005; 15:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/90\">",
"      Crisera CA, Grau JB, Maldonado TS, et al. Defective epithelial-mesenchymal interactions dictate the organogenesis of tracheoesophageal fistula. Pediatr Surg Int 2000; 16:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/91\">",
"      Goyal A, Jones MO, Couriel JM, Losty PD. Oesophageal atresia and tracheo-oesophageal fistula. Arch Dis Child Fetal Neonatal Ed 2006; 91:F381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/92\">",
"      Shaw-Smith C. Oesophageal atresia, tracheo-oesophageal fistula, and the VACTERL association: review of genetics and epidemiology. J Med Genet 2006; 43:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/93\">",
"      Pretorius DH, Drose JA, Dennis MA, et al. Tracheoesophageal fistula in utero. Twenty-two cases. J Ultrasound Med 1987; 6:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/94\">",
"      Sparey C, Jawaheer G, Barrett AM, Robson SC. Esophageal atresia in the Northern Region Congenital Anomaly Survey, 1985-1997: prenatal diagnosis and outcome. Am J Obstet Gynecol 2000; 182:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/95\">",
"      Karnak I, Senocak ME, Hi&ccedil;s&ouml;nmez A, B&uuml;y&uuml;kpamuk&ccedil;u N. The diagnosis and treatment of H-type tracheoesophageal fistula. J Pediatr Surg 1997; 32:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/96\">",
"      Zacharias J, Genc O, Goldstraw P. Congenital tracheoesophageal fistulas presenting in adults: presentation of two cases and a synopsis of the literature. J Thorac Cardiovasc Surg 2004; 128:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/97\">",
"      Laffan EE, Daneman A, Ein SH, et al. Tracheoesophageal fistula without esophageal atresia: are pull-back tube esophagograms needed for diagnosis? Pediatr Radiol 2006; 36:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/98\">",
"      Nagata K, Kamio Y, Ichikawa T, et al. Congenital tracheoesophageal fistula successfully diagnosed by CT esophagography. World J Gastroenterol 2006; 12:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/99\">",
"      Islam S, Cavanaugh E, Honeke R, Hirschl RB. Diagnosis of a proximal tracheoesophageal fistula using three-dimensional CT scan: a case report. J Pediatr Surg 2004; 39:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/100\">",
"      Dogan BE, Fitoz S, Atasoy C, et al. Tracheoesophageal fistula: demonstration of recurrence by three-dimensional computed tomography. Curr Probl Diagn Radiol 2005; 34:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/101\">",
"      Ko BA, Frederic R, DiTirro PA, et al. Simplified access for division of the low cervical/high thoracic H-type tracheoesophageal fistula. J Pediatr Surg 2000; 35:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/102\">",
"      Little DC, Rescorla FJ, Grosfeld JL, et al. Long-term analysis of children with esophageal atresia and tracheoesophageal fistula. J Pediatr Surg 2003; 38:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/103\">",
"      Orford J, Cass DT, Glasson MJ. Advances in the treatment of oesophageal atresia over three decades: the 1970s and the 1990s. Pediatr Surg Int 2004; 20:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/104\">",
"      Tsao K, Lee H. Extrapleural thoracoscopic repair of esophageal atresia with tracheoesophageal fistula. Pediatr Surg Int 2005; 21:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/105\">",
"      Krosnar S, Baxter A. Thoracoscopic repair of esophageal atresia with tracheoesophageal fistula: anesthetic and intensive care management of a series of eight neonates. Paediatr Anaesth 2005; 15:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/106\">",
"      Rothenberg SS. Thoracoscopic repair of esophageal atresia and tracheo-esophageal fistula. Semin Pediatr Surg 2005; 14:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/107\">",
"      Meier JD, Sulman CG, Almond PS, Holinger LD. Endoscopic management of recurrent congenital tracheoesophageal fistula: a review of techniques and results. Int J Pediatr Otorhinolaryngol 2007; 71:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/108\">",
"      Holcomb GW 3rd, Rothenberg SS, Bax KM, et al. Thoracoscopic repair of esophageal atresia and tracheoesophageal fistula: a multi-institutional analysis. Ann Surg 2005; 242:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/109\">",
"      Freire JP, Feij&oacute; SM, Miranda L, et al. Tracheo-esophageal fistula: combined surgical and endoscopic approach. Dis Esophagus 2006; 19:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/110\">",
"      Patkowsk D, Rysiakiewicz K, Jaworski W, et al. Thoracoscopic repair of tracheoesophageal fistula and esophageal atresia. J Laparoendosc Adv Surg Tech A 2009; 19 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/111\">",
"      Varjavandi V, Shi E. Early primary repair of long gap esophageal atresia: the VATER operation. J Pediatr Surg 2000; 35:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/112\">",
"      Spitz L. Oesophageal atresia treatment: a 21st-century perspective. J Pediatr Gastroenterol Nutr 2011; 52 Suppl 1:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/113\">",
"      van der Zee DC. Thoracoscopic elongation of the esophagus in long-gap esophageal atresia. J Pediatr Gastroenterol Nutr 2011; 52 Suppl 1:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/114\">",
"      Petrosyan M, Estrada J, Hunter C, et al. Esophageal atresia/tracheoesophageal fistula in very low-birth-weight neonates: improved outcomes with staged repair. J Pediatr Surg 2009; 44:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/115\">",
"      Teich S, Barton DP, Ginn-Pease ME, King DR. Prognostic classification for esophageal atresia and tracheoesophageal fistula: Waterston versus Montreal. J Pediatr Surg 1997; 32:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/116\">",
"      Choudhury SR, Ashcraft KW, Sharp RJ, et al. Survival of patients with esophageal atresia: influence of birth weight, cardiac anomaly, and late respiratory complications. J Pediatr Surg 1999; 34:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/117\">",
"      Konkin DE, O'hali WA, Webber EM, Blair GK. Outcomes in esophageal atresia and tracheoesophageal fistula. J Pediatr Surg 2003; 38:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/118\">",
"      Upadhyaya VD, Gangopadhyaya AN, Gupta DK, et al. Prognosis of congenital tracheoesophageal fistula with esophageal atresia on the basis of gap length. Pediatr Surg Int 2007; 23:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/119\">",
"      Engum SA, Grosfeld JL, West KW, et al. Analysis of morbidity and mortality in 227 cases of esophageal atresia and/or tracheoesophageal fistula over two decades. Arch Surg 1995; 130:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/120\">",
"      Antoniou D, Soutis M, Christopoulos-Geroulanos G. Anastomotic strictures following esophageal atresia repair: a 20-year experience with endoscopic balloon dilatation. J Pediatr Gastroenterol Nutr 2010; 51:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/121\">",
"      Michaud L, Gottrand F. Anastomotic strictures: conservative treatment. J Pediatr Gastroenterol Nutr 2011; 52 Suppl 1:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/122\">",
"      de Lagausie P. GER in oesophageal atresia: surgical options. J Pediatr Gastroenterol Nutr 2011; 52 Suppl 1:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/123\">",
"      Yanchar NL, Gordon R, Cooper M, et al. Significance of the clinical course and early upper gastrointestinal studies in predicting complications associated with repair of esophageal atresia. J Pediatr Surg 2001; 36:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/124\">",
"      Romeo C, Bonanno N, Baldari S, et al. Gastric motility disorders in patients operated on for esophageal atresia and tracheoesophageal fistula: long-term evaluation. J Pediatr Surg 2000; 35:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/125\">",
"      Legrand C, Michaud L, Salleron J, et al. Long-term outcome of children with oesophageal atresia type III. Arch Dis Child 2012; 97:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/126\">",
"      Robertson DF, Mobaireek K, Davis GM, Coates AL. Late pulmonary function following repair of tracheoesophageal fistula or esophageal atresia. Pediatr Pulmonol 1995; 20:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/127\">",
"      Gischler SJ, van der Cammen-van Zijp MH, Mazer P, et al. A prospective comparative evaluation of persistent respiratory morbidity in esophageal atresia and congenital diaphragmatic hernia survivors. J Pediatr Surg 2009; 44:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/128\">",
"      Delacourt C, de Blic J. Pulmonary outcome of esophageal atresia. J Pediatr Gastroenterol Nutr 2011; 52 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/129\">",
"      Beucher J, Wagnon J, Daniel V, et al. Long-term evaluation of respiratory status after esophageal atresia repair. Pediatr Pulmonol 2013; 48:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/130\">",
"      Taylor AC, Breen KJ, Auldist A, et al. Gastroesophageal reflux and related pathology in adults who were born with esophageal atresia: a long-term follow-up study. Clin Gastroenterol Hepatol 2007; 5:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/131\">",
"      Tomaselli V, Volpi ML, Dell'Agnola CA, et al. Long-term evaluation of esophageal function in patients treated at birth for esophageal atresia. Pediatr Surg Int 2003; 19:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/132\">",
"      Kovesi T, Rubin S. Long-term complications of congenital esophageal atresia and/or tracheoesophageal fistula. Chest 2004; 126:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/133\">",
"      Nasr A, Ein SH, Gerstle JT. Infants with repaired esophageal atresia and distal tracheoesophageal fistula with severe respiratory distress: is it tracheomalacia, reflux, or both? J Pediatr Surg 2005; 40:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/134\">",
"      Rintala RJ, Sistonen S, Pakarinen MP. Outcome of oesophageal atresia beyond childhood. J Pediatr Gastroenterol Nutr 2011; 52 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/135\">",
"      Jayasekera CS, Desmond PV, Holmes JA, et al. Cluster of 4 cases of esophageal squamous cell cancer developing in adults with surgically corrected esophageal atresia--time for screening to start. J Pediatr Surg 2012; 47:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/136\">",
"      Doolittle AM, Mair EA. Tracheal bronchus: classification, endoscopic analysis, and airway management. Otolaryngol Head Neck Surg 2002; 126:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/137\">",
"      Ghaye B, Szapiro D, Fanchamps JM, Dondelinger RF. Congenital bronchial abnormalities revisited. Radiographics 2001; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/138\">",
"      Gonlugur U, Efeoglu T, Kaptanoglu M, Akkurt I. Major anatomical variations of the tracheobronchial tree: bronchoscopic observation. Anat Sci Int 2005; 80:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/139\">",
"      Barat M, Konrad HR. Tracheal bronchus. Am J Otolaryngol 1987; 8:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/140\">",
"      Setty SP, Michaels AJ. Tracheal bronchus: case presentation, literature review, and discussion. J Trauma 2000; 49:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/141\">",
"      McLaughlin FJ, Strieder DJ, Harris GB, et al. Tracheal bronchus: association with respiratory morbidity in childhood. J Pediatr 1985; 106:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/142\">",
"      O'Sullivan BP, Frassica JJ, Rayder SM. Tracheal bronchus: a cause of prolonged atelectasis in intubated children. Chest 1998; 113:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/143\">",
"      Elmaci TT, G&uuml;ler N, Aydoan U, Onursal E. Infantile lobar emphysema and tracheal bronchus in a patient with congenital heart disease. J Pediatr Surg 2001; 36:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/144\">",
"      Kumagae Y, Jinguji M, Tanaka D, Nakajo M. An adult case of bilateral true tracheal bronchi associated with hemoptysis. J Thorac Imaging 2006; 21:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/145\">",
"      Morrison SC. Demonstration of a tracheal bronchus by computed tomography. Clin Radiol 1988; 39:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/146\">",
"      Yildiz H, Ugurel S, Soylu K, et al. Accessory cardiac bronchus and tracheal bronchus anomalies: CT-bronchoscopy and CT-bronchography findings. Surg Radiol Anat 2006; 28:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/147\">",
"      Ming Z, Lin Z. Evaluation of tracheal bronchus in Chinese children using multidetector CT. Pediatr Radiol 2007; 37:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/148\">",
"      Zylak CJ, Eyler WR, Spizarny DL, Stone CH. Developmental lung anomalies in the adult: radiologic-pathologic correlation. Radiographics 2002; 22 Spec No:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/149\">",
"      Langston C. New concepts in the pathology of congenital lung malformations. Semin Pediatr Surg 2003; 12:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/150\">",
"      Kunisaki SM, Fauza DO, Nemes LP, et al. Bronchial atresia: the hidden pathology within a spectrum of prenatally diagnosed lung masses. J Pediatr Surg 2006; 41:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/151\">",
"      Riedlinger WF, Vargas SO, Jennings RW, et al. Bronchial atresia is common to extralobar sequestration, intralobar sequestration, congenital cystic adenomatoid malformation, and lobar emphysema. Pediatr Dev Pathol 2006; 9:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/152\">",
"      Boogaard R, Huijsmans SH, Pijnenburg MW, et al. Tracheomalacia and bronchomalacia in children: incidence and patient characteristics. Chest 2005; 128:3391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/153\">",
"      Finder JD. Primary bronchomalacia in infants and children. J Pediatr 1997; 130:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/154\">",
"      Denneny JC 3rd. Bronchomalacia in the neonate. Ann Otol Rhinol Laryngol 1985; 94:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/155\">",
"      Sagy M, Poustchi-Amin M, Nimkoff L, et al. Spiral computed tomographic scanning of the chest with three dimensional imaging in the diagnosis and management of paediatric intrathoracic airway obstruction. Thorax 1996; 51:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/156\">",
"      De Wever W, Bogaert J, Verschakelen JA. Virtual bronchoscopy: accuracy and usefulness--an overview. Semin Ultrasound CT MR 2005; 26:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/157\">",
"      De Wever W, Vandecaveye V, Lanciotti S, Verschakelen JA. Multidetector CT-generated virtual bronchoscopy: an illustrated review of the potential clinical indications. Eur Respir J 2004; 23:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/158\">",
"      Colt HG, Dumon JF. Airway stents. Present and future. Clin Chest Med 1995; 16:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/159\">",
"      Lynch JI. Bronchomalacia in children. Considerations governing medical vs surgical treatment. Clin Pediatr (Phila) 1970; 9:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/160\">",
"      Rodgers BM, Harman PK, Johnson AM. Bronchopulmonary foregut malformations. The spectrum of anomalies. Ann Surg 1986; 203:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/161\">",
"      Kao CY, Sheu JC, Wang NL, et al. Incomplete duplication of trachea with bronchogenic cyst: a case report. J Pediatr Surg 2007; 42:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/162\">",
"      Pujary K, Pujary P, Shetty R, et al. Congenital cervical bronchogenic cyst. Int J Pediatr Otorhinolaryngol 2001; 57:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/163\">",
"      Sugita R, Morimoto K, Yuda F. Intrapleural bronchogenic cyst. Eur J Radiol 1999; 32:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/164\">",
"      Zvulunov A, Amichai B, Grunwald MH, et al. Cutaneous bronchogenic cyst: delineation of a poorly recognized lesion. Pediatr Dermatol 1998; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/165\">",
"      Sauvat F, Fusaro F, Jaubert F, et al. Paraesophageal bronchogenic cyst: first case reports in pediatric. Pediatr Surg Int 2006; 22:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/166\">",
"      Wei X, Omo A, Pan T, et al. Left ventricular bronchogenic cyst. Ann Thorac Surg 2006; 81:e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/167\">",
"      Maung KH, Low C, Knight LC, Cullinane CJ. Multiple cervical bronchogenic cysts. J Laryngol Otol 2006; 120:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/168\">",
"      Ozel SK, Kazez A, Koseogullari AA, Akpolat N. Scapular bronchogenic cysts in children: case report and review of the literature. Pediatr Surg Int 2005; 21:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/169\">",
"      Ustundag E, Iseri M, Keskin G, et al. Cervical bronchogenic cysts in head and neck region. J Laryngol Otol 2005; 119:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/170\">",
"      Gaikwad P, Muthusami JC, Raj JP, et al. Subcutaneous bronchogenic cyst. Otolaryngol Head Neck Surg 2006; 135:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/171\">",
"      Ko SF, Hsieh MJ, Lin JW, et al. Bronchogenic cyst of the esophagus: clinical and imaging features of seven cases. Clin Imaging 2006; 30:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/172\">",
"      Jo WM, Shin JS, Lee IS. Supradiaphragmatic bronchogenic cyst extending into the retroperitoneum. Ann Thorac Surg 2006; 81:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/173\">",
"      Teissier N, Elmaleh-Berg&egrave;s M, Ferkdadji L, et al. Cervical bronchogenic cysts: usual and unusual clinical presentations. Arch Otolaryngol Head Neck Surg 2008; 134:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/174\">",
"      Nobuhara KK, Gorski YC, La Quaglia MP, Shamberger RC. Bronchogenic cysts and esophageal duplications: common origins and treatment. J Pediatr Surg 1997; 32:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/175\">",
"      Evrard V, Ceulemans J, Coosemans W, et al. Congenital parenchymatous malformations of the lung. World J Surg 1999; 23:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/176\">",
"      Ribet ME, Copin MC, Gosselin BH. Bronchogenic cysts of the lung. Ann Thorac Surg 1996; 61:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/177\">",
"      Al-Bassam A, Al-Rabeeah A, Al-Nassar S, et al. Congenital cystic disease of the lung in infants and children (experience with 57 cases). Eur J Pediatr Surg 1999; 9:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/178\">",
"      Sarper A, Ayten A, Golbasi I, et al. Bronchogenic cyst. Tex Heart Inst J 2003; 30:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/179\">",
"      Patel SR, Meeker DP, Biscotti CV, et al. Presentation and management of bronchogenic cysts in the adult. Chest 1994; 106:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/180\">",
"      Kanemitsu Y, Nakayama H, Asamura H, et al. Clinical features and management of bronchogenic cysts: report of 17 cases. Surg Today 1999; 29:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/181\">",
"      Tireli GA, Ozbey H, Temiz A, et al. Bronchogenic cysts: a rare congenital cystic malformation of the lung. Surg Today 2004; 34:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/182\">",
"      Dembinski J, Kaminski M, Schild R, et al. Congenital intrapulmonary bronchogenic cyst in the neonate--perinatal management. Am J Perinatol 1999; 16:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/183\">",
"      Harle CC, Dearlove O, Walker RW, Wright N. A bronchogenic cyst in an infant causing tracheal occlusion and cardiac arrest. Anaesthesia 1999; 54:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/184\">",
"      De Baets F, Van Daele S, Schelstraete P, et al. Asphyxiating tracheal bronchogenic cyst. Pediatr Pulmonol 2004; 38:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/185\">",
"      Jackson A, Simpson J, Coutts J. Case 1: an unusual cause of respiratory distress at birth. Diagnosis: bronchogenic cyst occluding the trachea. Acta Paediatr 2006; 95:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/186\">",
"      Hernanz-Schulman M. Cysts and cystlike lesions of the lung. Radiol Clin North Am 1993; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/187\">",
"      McAdams HP, Kirejczyk WM, Rosado-de-Christenson ML, Matsumoto S. Bronchogenic cyst: imaging features with clinical and histopathologic correlation. Radiology 2000; 217:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/188\">",
"      de Perrot M, Pache JC, Spiliopoulos A. Carcinoma arising in congenital lung cysts. Thorac Cardiovasc Surg 2001; 49:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/189\">",
"      Yoshida M, Kondo K, Toba H, et al. Two cases of bronchogenic cyst with severe adhesion to the trachea. J Med Invest 2007; 54:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/190\">",
"      Funakoshi Y, Takeda S, Kadota Y, Maeda H. Mediastinal bronchogenic cyst with respiratory distress from airway and vascular compression. Thorac Cardiovasc Surg 2007; 55:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/27/29114/abstract/191\">",
"      Rose SH, Elliott BA, Brown MJ, et al. Perioperative risk associated with an unrecognized bronchogenic cyst: clinical significance and anesthetic management. J Cardiothorac Vasc Anesth 2007; 21:720.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6377 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-71A5527948-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29114=[""].join("\n");
var outline_f28_27_29114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRACHEAL ATRESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TRACHEAL STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TRACHEOMALACIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INTRINSIC TRACHEAL OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TRACHEOESOPHAGEAL FISTULA AND ESOPHAGEAL ATRESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TRACHEAL BRONCHUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      LOWER AIRWAY ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bronchial atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Bronchial stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Bronchomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Bronchial obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bronchogenic cyst",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6377\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6377|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/5/15441\" title=\"diagnostic image 1\">",
"      Chest XRay bronchogenic cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/6/34912\" title=\"diagnostic image 2\">",
"      CT bronchogenic cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6377|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/26/41382\" title=\"figure 1\">",
"      Types of TEF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6377|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/8/18563\" title=\"picture 1\">",
"      Gross path bronchogenic cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/39/32373\" title=\"picture 2\">",
"      Histopath bronchogenic cyst",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19161?source=related_link\">",
"      Approach to congenital malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=related_link\">",
"      Congenital anomalies of the nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30487?source=related_link\">",
"      Radiographic appearance of developmental anomalies of the lung",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_27_29115="Frequency of maternal blood lead follow-up testing";
var content_f28_27_29115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of maternal blood lead follow-up testing during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Venous blood lead level (BLL; &micro;g/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perform follow-up test(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        None (no follow-up testing is indicated).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-14",
"       </td>",
"       <td>",
"        Within 1 month. Obtain a maternal BLL* or cord BLL at delivery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-24",
"       </td>",
"       <td>",
"        Within 1 month and then every 2-3 months. Obtain a maternal BLL* or cord BLL at delivery. More frequent testing may be indicated based on risk factor history.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-44",
"       </td>",
"       <td>",
"        Within 1-4 weeks and then every month. Obtain a maternal BLL* or cord BLL at delivery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;45",
"       </td>",
"       <td>",
"        Within 24 hours and then at frequent intervals depending on clinical interventions and trend in BLLs. Consultation with a clinician experienced in the management of pregnant women with BLLs in this range is strongly advised. Obtain a maternal BLL* or cord BLL at delivery.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If possible, obtain a maternal BLL prior to delivery since BLLs tend to rise over the course of pregnancy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ettinger AS, Wengrovitz AG. Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women. Centers for Disease Control and Prevention. November 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29115=[""].join("\n");
var outline_f28_27_29115=null;
var title_f28_27_29116="Causes of anemia";
var content_f28_27_29116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of anemia in the adult",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low mean corpuscular volume (microcytic anemia: MCV &lt;80 fL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron deficiency anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thalassemic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia of inflammation/anemia of chronic disease (late; uncommon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sideroblastic anemia (eg, congenital, lead, alcohol, drugs; uncommon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper deficiency, zinc poisoning (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Normal mean corpuscular volume (normocytic anemia: MCV 80 to 100 fL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute blood loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron deficiency anemia (early)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia of inflammation/anemia of chronic disease (eg, infection, inflammation, malignancy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Bone marrow suppression (may also be macrocytic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bone marrow invasion (eg, leukoerythroblastic blood picture)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acquired pure red blood cell aplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aplastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Endocrine dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypopituitarism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased mean corpuscular volume (macrocytic anemia: MCV &gt;100 fL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Folate deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12 deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelodysplastic syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myeloid leukemias (eg, erythroleukemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Reticulocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemolytic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Response to blood loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Response to appropriate hematinic (eg, iron, B12, folic acid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced anemia (eg, Hydroxyurea, AZT, chemotherapeutic agents)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     This list is not meant to be exhaustive; only the most common causes are mentioned. In addition, two or more of these conditions may be present (eg, combined iron and folate deficiencies), resulting in a misleadingly normal mean corpuscular volume.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29116=[""].join("\n");
var outline_f28_27_29116=null;
var title_f28_27_29117="Theophylline effect in asthma";
var content_f28_27_29117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Lack of effect of theophylline in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Change in total asthma score during hospital stay in patients treated with theophylline or placebo, showing the mean regression line of the asthma score until the time that discharge criteria were achieved (asthma score = 2). There was no difference between the two groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From DiGiulio, GA, Kercsmar, CM, Krug, SE, et al, J Pediatr 1993; 122:464.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29117=[""].join("\n");
var outline_f28_27_29117=null;
var title_f28_27_29118="Contents: Urogynecology";
var content_f28_27_29118=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Urogynecology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Urogynecology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Pelvic relaxation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/33/40473\">",
"           An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/47/4857\">",
"           Clinical manifestations, diagnosis, and nonsurgical management of posterior vaginal defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34263\">",
"           Delayed surgical management of the disrupted anal sphincter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/56/9097\">",
"           Fecal incontinence related to pregnancy and vaginal delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25976\">",
"           Laparoscopic surgery for repair of pelvic floor defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/62/26602\">",
"           Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/18/19753\">",
"           Pelvic floor disorders associated with pregnancy and childbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/32/1546\">",
"           Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/7/9337\">",
"           Pelvic organ prolapse in women: Choosing a primary surgical procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/46/8937\">",
"           Pelvic organ prolapse in women: Diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/37/43607\">",
"           Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/8/7306\">",
"           Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/4/35914\">",
"           Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/33/11799\">",
"           Reconstructive materials used in surgery: Classification and host response",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/24/44424\">",
"           Surgical management of posterior vaginal defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17530\">",
"           Vaginal pessary treatment of prolapse and incontinence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/14/29929\">",
"           Clinical presentation and diagnosis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/57/29592\">",
"           Diagnostic cystourethroscopy for gynecologic conditions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/1/7192\">",
"           Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/22/43369\">",
"           Management of interstitial cystitis/bladder pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/8/8330\">",
"           Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/32/1546\">",
"           Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32951\">",
"           Rectovaginal, anovaginal, and colovesical fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43177\">",
"           Stress urinary incontinence in women: Choosing a primary surgical procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/43/16055\">",
"           Stress urinary incontinence in women: Choosing a type of midurethral sling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/23/44409\">",
"           Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/58/17319\">",
"           Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/49/33562\">",
"           Stress urinary incontinence in women: Retropubic midurethral slings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33401\">",
"           Stress urinary incontinence in women: Transobturator midurethral slings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/4/32842\">",
"           Treatment of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/15/26873\">",
"           Urethral diverticulum in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/23/32120\">",
"           Urodynamic evaluation of women with incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/47/44792\">",
"           Urogenital tract fistulas in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19336\">",
"           Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-60394325AF-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_27_29118=[""].join("\n");
var outline_f28_27_29118=null;
var title_f28_27_29119="Types of episiotomy incision";
var content_f28_27_29119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Types of episiotomy incisions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 457px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    1 = Median incision, 1+2 = \"T\" incision, 3 = \"J\" incision, 4 = Mediolateral incision, 5 = Lateral incision",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_27_29119=[""].join("\n");
var outline_f28_27_29119=null;
